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Dekan
The ancient dragon of Africa the trypanosome is firmly entrenched. Like Tol-
kien’s Smaugh, it sometimes slumbers and smoulders quietly for long periods
but at any moment it may awaken and cause widespread loss of life to man and
his domestic animals (Maegraith, 1970).
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Summary
Trypanosomiasis remains a major threat to humans in sub-Saharan Africa with 55-60
million people in 36 countries at risk of infection with T.b. gambiense or T.b. rhodesi-
ense. Only a few drugs are available to treat the disease, which are either toxic,
scarce, or do not readily pass the blood brain barrier to achieve therapeutic levels in
the brain. A new drug is not in sight. The organo-arsenical compound melarsoprol is
the main drug in use for therapy of the late stage of the disease, with central nervous
system involvement. During melarsoprol treatment patients often suffer from serious
adverse effects such as fever, diarrhea, pruritus and in 2-10% of the cases from reac-
tive encephalopathy with fatal outcome in 50%. Although melarsoprol was introduced in
1949 there is a lack of data on its metabolites, pharmacologic or chemical properties.
The present PhD project had two objectives: Firstly to analyze, characterize and de-
termine the pharmacokinetics of the metabolites of the trypanocidal drug melarsoprol
(the pharmacokinetics of relapse patients were additionally investigated). Secondly to
evaluate further possible drug candidates for treatment of trypanosomiasis by structure
activity relationship: In this study a group of antibacterial agents, the fluoroquinolones,
was examined.
A HPLC-UV method was developed to separate the parent drug melarsoprol from its
potential metabolites. One metabolite could be identified after incubation of the drug
with microsomes and also in serum of patients treated with melarsoprol: Melarsen ox-
ide. Interestingly, this trypanocidal drug was in use before the development of melarso-
prol, which is the condensation product of melarsen oxide and dimercaprol (an antidote
for arsenic poisoning). After administration of 2.2 mg/kg of melarsoprol Cmax of melar-
sen oxide was reached after 5-15 minutes, the clearance was found to be 21.5
ml/min/kg and a half life of 3.8 hours was calculated. The therapeutic value of melarsen
oxide was investigated in in vivo mice experiments: It could be demonstrated that the
drug passes the blood brain barrier, hence might be an alternative to melarsoprol.
Investigations on additional metabolites revealed that melarsen oxide or its arsenical
derivatives are irreversibly bound to proteins. Covalent protein bound drugs are often
associated with serious immunological adverse effects.
The bacteriocidal class of fluoroquinolones act via the inhibition of topoisomerases.
These enzymes mediating topological changes in the DNA are essential for cell sur-
vival. Trypanosomes possess a condensed, topologically interlocked circular type of
mitochondrial DNA. The high demand for topoisomerase activity in combination with
the rapid proliferation of trypanosomes makes the inhibition of topoisomerases an in-
teresting drug target. 160 fluoroquinolones were tested against T.b. rhodesiense in vi-
tro, with several compounds found to be active in the nanomolar range. The R7 sub-
stitution of the quinolone core was of importance for activity, whereas structural modifi-
cation of the quinolone structure at position R1, R2, R3, and R8 did not influence try-
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panocidal activity. In vitro cytotoxicity was determined for active compounds and sub-
sequently six compounds were selected for further in vivo evaluation. However, even
after the administration of high doses (100 mg/kg) no parasitological cure of the mice
could be achieved.
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Zusammenfassung
Etwa 55-60 Millionen Menschen, in Gebieten südlich der Sahara, sind bedroht von
Trypanosomen, den Erregern der afrikanischen Schlafkrankheit, infiziert zu werden.
Für die Behandlung stehen nur wenige Medikamente zur Verfügung und zur Zeit
werden keine neuen Medikamente entwickelt. Die organo-arsen Verbindung
Melarsoprol ist die meist verwendete Substanz zur Therapie des Spätstadiums der
Krankheit, nachdem die Erreger das Zentralnervensystems befallen haben. Die
Therapie wird begleitet von schweren Nebenwirkungen wie Fieber, Durchfall, Juckreiz
und in 2-10% der Fälle von reaktiven Encephalopathien, die in 50% tödlich enden.
Melarsoprol wurde schon 1949 zur medikamentösen Krankheitskontrolle eingeführt,
dennoch sind pharmakologische, pharmakokinetische oder chemische Eigenschaften
bis heute weitgehend unerforscht.
Zwei Möglichkeiten, für die Entwicklung von Leitsubstanzen für die Therapie von
Trypanosomiasis werden in der vorliegenden Doktorarbeit präsentiert: Erstens die
Aufklärung, Charakterisierung und Pharmakokinetik der Metaboliten von Melarsoprol.
mit zusätzlicher Untersuchung der Pharmakokinetik von Therapieversagern. Zweitens
die Durchführung einer Struktur-Aktivitätsbeziehungsstudie gegenüber Trypanosomen
am Beispiel der antibiotischen Substanzgruppe der Fluoroquinolone.
Für die Trennung von Melarsoprol von seinen Stoffwechselprodukten und deren
Identifikation in Blutproben und Leberzellinkubationen wurde eine HPLC-UV Methode
entwickelt. Mittels dieser konnte ein aktiver Metabolit bestimmt werden: Melarsenoxid,
welches interessanterweise der Vorgänger von Melarsoprol, dem
Kondensationsprodukt aus Melarsenoxid und Dimercaprol (ein Antidot gegen
Arsenvergiftungen) war. Nach Applikation einer Dosis von 2.2 mg/kg Melarsoprol
werden Spitzenplasmakonzentrationen von Melarsenoxid nach 5-15 Minuten erreicht,
die durchschnittliche Halbwertszeit von Melarsenoxid ist 3.8 h und die Clearance
beträgt 21.5 ml/min/kg. In einem in vivo Mausexperiment konnte die Blut-
Hirngängigkeit von Melarsenoxid demonstriert werden, somit weist der hydrophilere
Metabolit Potential für einen Einsatz in der Therapie des Spätstadiums der Krankheit
auf.
Weitere Untersuchungen ergaben, dass Melarsenoxid, oder arsenhaltige Metaboliten
dieser Substanz, irreversibel proteingebunden sind. Da kovalent gebundene Protein-
Arzneikomplexe eine Immunantwort hervorrufen können, könnte dies eine mögliche
Ursache der schweren Nebenwirkungen von Melarsoprol sein.
Fluoroquinolone, Gyrasehemmer werden häufig für die Therapie von bakteriellen
Infektionskrankheiten eingesetzt. Diese Antibiotika hemmen lebenswichtige Enzyme,
die sogenannten Topoisomerasen, die verantwortlich für das Schneiden von DNA
Strängen sind, und dadurch das Absterben der Bakterienzelle bewirken. Da
Zusammenfassung                                                                                                                        4
Trypanosomen eine hohe Teilungsrate und eine grosse DNA Dichte besitzen, lässt
sich eine Sensitivität gegenüber Fluoroquinolone vermuten.
In der Studie wurden 160 Fluoroquinolonderivate in vitro getestet, und einige dieser
Substanzen wiesen Aktivität gegenüber Trypanosomen im Konzentrationsbereich von
100–1000 ng/ml auf. Für die Aktivtät gegenüber Trypanosomen war besonders die R7
Substitution des Quinolon- Grundgerüstes wichtig, wogegen die R1, R2, R3 und R8
Substitution nicht von Bedeutung zu sein scheint. Von den aktiven Substanzen wurde
die in vitro Toxizität ermittelt, und anschliessend sechs Derivate mit geringer Toxizität
in vivo getestet. Diese zeigten jedoch im Mausmodell auch in hohen Dosen keine
Wirkung auf Trypanosomen.
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Introduction
Biological and historical background of human African trypanosomiasis
The parasite
Human African trypanosomiasis (HAT), sleeping sickness, is caused by the protozoan
parasites Trypanosoma brucei (T.b.) gambiense and T.b. rhodesiense. T.b. brucei is
not infective to humans. Trypanosoma brucei belong to the genus Trypanosoma and
are classified in the phylum Sarcomastigophora, the order Kinetoplastida and the family
Trypanosomatidae. The parasites are transmitted to the mammalian host by the bite of
tsetse flies (several Glossina species) during the probing and feeding process of both
sexes. T.b. gambiense is endemic throughout West and Central Africa. The course of
the disease is slow and chronic- sometimes years elapse before specific symptoms
become obvious. Nevertheless, the outcome is fatal due to extensive involvement of
the central nervous system. Transmission of T.b. gambiense infection is anthroponotic,
humans are the preferred host, however pigs, dogs and cattle can act as reservoirs
(Molyneux, Pentreath et al., 1996).
T.b. rhodesiense, occurring in East Africa, is the causative agent of the acute form of
the disease. Severe clinical signs are developed within days following the infection. A
number of livestock and game animals can act as reservoirs for T.b. rhodesiense,
Glossina spp. are preferentially bovid feeders and not attracted to humans, therefore
only feed on humans when other hosts are not available (Molyneux, Pentreath et al.,
1996).
The economic and social impact of animal trypanosomiasis caused by T. congolense,
T. vivax, T. evansi and T. equiperdum is tremendous: About seven million cattle die
annually in the “tsetse-belt”, thus diminishing important protein sources (Hajduk, Adler
et al., 1992).
The life cycle of trypanosomes involves two hosts: A mammalian and an intermediate
insect host or vector, which transmits the infection to a new mammalian host. Trypano-
somes are characterized by the position of the nucleus relative to the kinetoplast, an
organelle associated with the mitochondrion and containing a condensed network of
circular DNA. Trypanosomes range in length from 15-35 mm (Bales, 1988). In the epi-
mastigote stage, in the insect vector, the kinetoplast is anterior to the nucleus. Trypo-
mastigotes, the slender forms found in the mammalian blood possess a subterminal ki-
netoplast.
The trypomastigote bloodstream forms of mammalian trypanosomes are basically
lanceolate in shape, their body having the form of an elongated flattened blade, which
is elliptic or oval in transverse section, while it ends taper to a point (Hoare, 1972).
Two distinct morphological forms are seen in the bloodstream infection: Early in the
infection rapidly dividing long, slender forms predominate, which are even able to cross
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the blood brain barrier and invade the cerebrospinal fluid in the advanced stage of the
infection. Non-dividing short stumpy forms are seen at peak levels and during declining
of parasitemia (Vickerman, 1985).
In 1909, the German scientist Kleine could prove that trypanosomes had to undergo a
cycle of development in the tsetse fly. This cycle is complex with many morphological,
physiological, biochemical changes and migration of the parasite: Briefly, trypomasti-
gotes are ingested from an infected mammalian host by the tsetse fly during its blood
meal. Only the stumpy forms of T. brucei are capable of initiating the cycle in the vec-
tor: In the midgut they transform to procyclic forms. The procyclics proliferate in the
ectoperitrophic space between the midgut and the peritrophic membrane. After 10-12
days they move to the proventriculus. Transformed into the slender and non-infective
epimastigotes, they migrate via the hypopharynx to the salivary glands. Epimastigotes
further differentiate during 15-35 days, depending on temperature and humidity of the
environment, into stumpy trypomastigote forms and mammal infective metacyclics.
With the bite of the tsetse fly the metacyclics are injected into the mammalian skin
where they transform into long slender trypomastigote forms and evade into the blood
and lymphatic system (Vickerman, 1985).
The disease
Trypanosomiasis is an ancient disease and written records go back as far as the 14th
century: An Arab writer described the death of Mansa Djata, the ruler of the Malli King-
dom (Niger):
“His end was to be overtaken by the sleeping sickness which is a disease that fre-
quently befalls the inhabitants of these countries especially their chieftains. Sleep
overtakes one of them in such a manner that it is hardly possible to awake him. He (the
king) remained in this condition during two years, until he died”.
In 1843 Gruby, a doctor from Vienna, isolated trypanosomes from the blood of a frog
and created the generic name Trypanosoma. During the 35 years that followed little
advance was made: In 1880 Griffith Evans, a veterinary officer, could demonstrate the
pathologic connection of this organism to animal diseases. Sir D. Bruce made the most
important contribution of subsequent investigations leading to the understanding of Na-
gana in cattle as a trypanosome infection (T. brucei). He also demonstrated that the
disease was transmitted by tsetse flies and that game animals acted as reservoirs of
the infection. In 1902 human trypanosomes were detected by Dutton in a European
patient returning from Gambia and his irregular fever attacks related to the parasite
(T.b. gambiense). The pathogenicity of trypanosomes was first demonstrated in 1903
by Castellani, who associated trypanosomes with sleeping sickness by finding them in
the cerebrospinal fluid of an Ugandan patient (“when examining a specimen of cere-
brospinal fluid taken by lumbar puncture … I was surprised to observe a living trypano-
soma… my eye had been attracted by a little fish like parasite darting about”)
(Bentivoglio, Grassi-Zucconi et al., 1994). Seven years later another trypanosomal or-
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ganism was isolated from the blood of a European returning from Rhodesia (T.b. rho-
desiense). During the same period some of the most important trypanosomes affecting
livestock and other domestic animals were described and their life cycles determined
e.g. T. equiperdum in 1901 or T. congolense in 1904 (Hoare, 1972; Bales, 1988).
Several devastating epidemics occurred due to an increased movement of people after
the arrival of European explorers and because of lacking knowledge of the epidemio-
logy and transmission of the disease. The disease expanded from restricted foci into
large endemic regions. Between 1896 and 1906 half a million people had died along
the river Congo, and the outbreak on the northern shore of Lake Victoria killed about
250,000 people (Bales, 1988).
By the late 1950’s the incidence of sleeping sickness has been greatly reduced by
mass campaigns of active case finding, chemotherapeutic treatment and vector control.
The independence from colonial power and subsequent civil disturbances, declining
economies and reduced health financing led to a dramatic resurgence of HAT (Smith,
Pepin et al., 1998).
Actual situation
It is estimated that 60 million people living in around 200 discrete transmission zones in
36 sub-Saharan countries are at risk of acquiring sleeping sickness. The disease is
only endemic in areas where tsetse flies are found, i. e. the tsetse belt: from approxi-
mately 14°N from Senegal in the West to 10°N in Southern Somalia in the East and
20°S corresponding to the northern fringes of the Kalahari and Namibian deserts
(Molyneux, Pentreath et al., 1996).
The incidence of annual cases is currently estimated at 300,000, in certain villages of
the Democratic Republic of Congo and in Angola the reported prevalence is up to 80%.
In some provinces the mortality rate of sleeping sickness is of the same order of mag-
nitude as the one caused by AIDS (UNDP, 1997).
Although trypanosomiasis is considered less important than malaria or AIDS, it remains
a continuous threat to humans. The symptoms are dramatic, the mortality rate is nearly
100%, if untreated, and epidemic outbreaks drive people away from their villages, thus
reducing productivity and threatening domestic livestock.
While sleeping sickness has declined in a number of West African countries, vast areas
of Central Africa from Southern Sudan and Uganda, through the Democratic Republic
of Congo to Angola are experiencing progressive epidemic spread (Smith, Pepin et al.,
1998).
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The situation in Angola
Gambian HAT was first recognized in northern Angola in the late 19th century. In re-
sponse the Portuguese Colonial Government put emphasis on control and created a
national surveillance program (Missão de Combate as Tripanosomiase). Each village
was visited at least once every year and access to diagnosis and treatment to the
whole population was guaranteed. The incidence of HAT was reduced from 5,000
cases in 1950 to only 3 cases 1974. In 1976, Angola became independent and the
country was thrown into a cruel civil war until today. One of the consequences was the
complete collapse of the health system and the discontinuation of the control program.
Since 1994 governmental activities focus on the establisment of treatment centers, ac-
tive case finding, health eduction and vector control (Smith, Pepin et al., 1998).
Today, Angola is one of the most affected countries by HAT, especially the northern
parts of the country, where sleeping sickness is the major cause of adult mortality
(Smith, Pepin et al., 1998). In the last six years, 22,560 cases have been diagnosed,
almost exclusively through passive case finding. In 1997 alone, 8,275 new cases were
detected, although active case finding was covering only 2% of the 4 million population
at risk (Van Nieuwenhove, 1998).
Clinical manifestation and pathogenesis
Signs and symptoms are classified according to the clinical progression of the disease:
the initial trypanosomal chancre, followed by the haematolymphatic or first stage, and
the meningoencephalitic or second stage (when parasites have invaded the central
nervous system (CNS). The clinical classification of the second stage of the disease is
mainly limited to crude measurements of changes in the cerebrospinal fluid (CSF). The
clinical signs vary between individuals and disease foci and are not always specific
(WHO, 1998).
A few days after the bite of an infected tsetse fly a chancre, a tender, painful and local
swelling, is frequently observed in T.b. rhodesiense infections. This primary lesion can
last up to several weeks. In its fluid trypanosomes are detectable. The chancre is less
common with T.b. gambiense infections.
Fever, resulting from an evasion of the parasites into the blood and their production of
pharmacologically active substances is accompanied by other unspecific symptoms.
Frequent complaints are headache, weight loss, joint pains, skin rashes, pruritus, ane-
mia or endocrine disorders. Sometimes the symptoms are minor and may not alert the
patients to seek medical advice. An enlargement of the lymph glands is often seen: In
T.b. gambiense infections the posterior cervical lymph nodes (Winterbottom’s sign) are
firm, mobile, painless and vary in size (WHO, 1998). Lymphadenopathy is usually gen-
eralized in patients suffering from T.b. rhodesiense infections (WHO, 1998). In both
forms of the disease an enlargement of the spleen and the liver can be observed.
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The brain, heart and lung are the most severely affected organs: Dysrhythmia, heart
murmurs and low blood pressure may be revealed. Pericardial effusion, myocarditis
and cerebral and meningeal edema are frequent symptoms in the second stage of dis-
ease.
The involvement of the CNS may occur within a few weeks in T.b. rhodesiense infec-
tions or may not occur until years later (T.b. gambiense infections). The organisms
penetrate into the brain tissue and produce inflammatory lesions. The onset of this
stage is insidious with progressive involvement. Early changes and symptoms involve
abnormal body movements, extrapyramidal signs, tremors, irritability, and alterations in
mood, indifference or the classical reversal of the sleep rhythm with daytime somno-
lence and night insomnia. As the disease progresses the neurologic abnormalities be-
come more marked: Epileptiform seizures may occur as well as local paralyses, ma-
niacal chances, total indifference and somnolence leading to coma and death. Due to
the long duration of T.b. gambiense infections extensive neurological changes might be
observed, which lead next to acute infections or malnutrition to death. In acute T.b.
rhodesiense disease death often occurs before CNS involvement because of cardiac
failures, pneumonia or superimposed infectious diseases (Molyneux, Pentreath et al.,
1996).
The mechanisms of pathogenicity are only poorly understood; most theories suggest
immunopathologic and biochemical processes. High parasitaemia results in an expo-
sure of the host to high levels of toxic metabolites, lytic enzymes and immunosuppres-
sive membrane components, which induce unregulated lymphocyte proliferation and
destructive inflammatory responses (WHO, 1998). The pathogenesis is ultimately
linked to the inability of the untreated patient to remove the parasite, since trypano-
somes escape the immune system by varying their surface glycoproteine coat (Bales,
1988). These variant surface glycoproteins (VSG’s) are strongly immunogenic and elicit
high levels of IgM antibodies.
It has been suggested that high IgM levels increase osmotic pressure, erythrocyte
sedimentation rate and blood viscosity. Circulating immune complexes activate the kal-
likrein, kinin, complement and blood coagulation systems, which lead to increased vas-
cular permeability, edema, inflammation and tissue damage (WHO, 1998). In addition
the production of autoantibodies directed against antigenic components of e.g. brain
and heart, is often discussed (Bales, 1988).
Treatment
In 1902 the first in vivo model became available and experimental treatment of try-
panosome infections were carried out. Out of a large number of preparations tested by
P. Ehrlich only trypan red and arsenic compounds were found to be highly effective.
Therefore chemotherapeutic research progressed mainly in two lines: the synthetic
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dyes and related compounds (e. g. suramin) and the organic arsenicals (e.g. melarso-
prol) (Drews, 1998).
Currently only four drugs are available for the treatment of HAT: Suramin (1922) and
pentamidine (1940) are used for the treatment of the first stage, melarsoprol (1949)
and eflornithine (1990) for the late stage of disease. These drugs have many adverse
effects, are expensive and are not readily available (WHO, 1998).
The treatment with arsenical drugs
More than 12,000 arsenical compounds were synthesized in the first half of this century
and screened for their activity against sleeping sickness (Friedheim, 1973). One of
them, melarsoprol (Mel B) is still the drug of choice for treatment of the late stage of
disease.
The treatment of trypanosomiasis with arsenicals has a long history:
Potassium arsenite was the first drug described to affect trypanosomes. The prime
consideration appears to have been the tonic effect of the drug, it was commonly pre-
scribed (in small doses!) against conditions of weakness, rather than the anti-protozoan
action. Potassium arsenite, also known as Fowler’s solution marks the beginning of
chemotherapy of sleeping sickness in 1887: Trekking from the east African coast to-
wards west and passing tsetse infested habitats, Dr. Livingstone’s horse fell sick and
was cured with a solution of 1% potassium arsenite (AsO2). Unfortunately the im-
provement was followed by a relapse. After offering the horse another dose the animal
turned its head and said: “dear Dr. Livingstone, I don’t want your medicine, let me die in
peace” (Friedheim and Distefano, 1989).
In 1905 the first organic arsenical Atoxylâ  (sodium-p-amino-phenyl arsonate), which
had already been synthesized in 1863 was brought to the market against febrile condi-
tions and syphilis. The aliphatic arsenic compounds were prepared accidentally. Al-
though Atoxylâ , which originated as a by-product of parafuchsin “did not exercise any
destructive action on the parasites in the test tubes” it was found to be highly active in
T.b. gambiense infections in vivo and 30 times less toxic than Fowler’s solution
(Williamson, 1970). A major drawback, however, was its toxicity affecting the optic
nerve; moreover relapses were the rule and therefore it did not justify its early hopes. It
cured only early cases of the disease and patients with T.b. rhodesiense infections re-
mained incurable (Williamson, 1970, Friedheim, 1989).
                                                                           Fig.1 Atoxyl
AsO3HNaNH2
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In the following years many derivatives of Atoxylâ  were synthesized and tested for their
trypanocidal activity. It was demonstrated that trivalent arsenic compounds were more
active, but also more toxic than the pentavalent arsenicals (Williamson, 1970). Among
the derivatives of Atoxylâ  were salvarsan (1910), a drug highly active against syphilis,
and tryparsamide the first late stage drug of trypanosomiasis. Heidelberger and
Jacobs developed tryparsamide in 1918, in order to improve the bad solubility and
chemical instability of the trivalent salvarsan. Trials of tryparsamide were carried out in
1920 in the then Belgian Congo. The drug was significantly more active in second
stage T.b. gambiense infections than Atoxylâ  but not active in T.b. rhodesiense infec-
tions. Its therapeutic index was found to be six times higher than the one of Atoxylâ .
Nevertheless, tryparsamide still exhibited a dose-dependent toxicity against the optic
nerve leading to a disastrous incidence in 1930: A young lieutenant doubled the pre-
scribed dose of the drug on a Monday morning resulting two days later in 800 blind pa-
tients. Furthermore, following mass treatment, tryparsamide resistant cases appeared
in increasing numbers (Friedheim, 1959, Williamson, 1970).
                                                                                  Fig.2 Tryparsamide
Enormous efforts were made to improve atoxyl and tryparsamide. In British, French
and German laboratories 12,500 arsenic compounds had been synthesized by 1932.
Also Dr. Friedheim was prompted by the fatal incidence on the optic nerve to develop
alternative arsenical drugs not endangering vision.
He even converted his own kitchen into a laboratory. In his first line of investigations he
linked sulphonic acid radicals to Atoxylâ  (compound 2654) (Friedheim, 1959) to elimi-
nate the toxic effects on the optic nerve. Sulphonic acids are largely dissociated under
physiological conditions and the resulting ions have no negative effect on the brain and
the optic nerve. The effectiveness of the drug could be demonstrated in a study in Ni-
geria but compound 2654 was later abandoned. One of the reasons for withdrawal
might have been the colored urine due to elimination of the purple compound by the
kidneys (Friedheim, 1959). In addition, the slow effect of the sulphonic acids on the try-
panosomes and thus necessary long treatment motivated Friedheim to do further in-
vestigations. He noticed that all arsenicals possessing a significant trypanocidal activity
contained nitrogen in one form or another. The melamine chemistry, famous in the
manufacture of plastic, offered a favorable start for the synthesis of new compounds.
AsO3H NaH 2NC OH 2NH
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Friedheim started with 2,4-Dichloro-s-triazinyl-6 aminophenyl-arsonic acid, a toxic sub-
stance of no therapeutic value and replaced the two halogens by unsubstituted amino
groups. This replacement resulted in a maximum trypanocidal effect combined with
minimum toxicity in mice (Friedheim, 1944): This first melamine compound was melar-
sen (1938). The drug was used in therapy the following years but its therapeutic effect
was controversial: Duggan and Hutchison (1951) reported the cure of 200 cases in Ni-
geria, Friedheim himself noticed severe adverse effects such as epileptic convulsions,
especially in malnourished people (Duggan and Hutchinson, 1951, Friedheim, 1959).
Melarsen was not totally abandoned and its efficacy was investigated in further trials.
The drug was found to be less toxic than earlier drugs, water soluble, thus easy to ad-
minister but more expensive. This might have been the main reason for its withdrawal
(Williamson, 1962).
                                                                           Fig.3 Melarsen
Bearing in mind Ehrlich’s demonstration of the higher activity (up to 250,000 times) of
trivalent arsenicals compared to the pentavalent forms, Friedheim synthesized in 1939
melarsen oxide. It was obtained from melarsen by simple reduction with sulfur dioxide
in the presence of HCl (Friedheim, 1948). Good cures were achieved with melarsen
oxide in several trials but the drug was later abandoned in favor of melarsoprol.
Melarsoprol is the condensation product of melarsen oxide with dimercaprol, also
known as British Anti Lewisite (BAL), an arsenic antidote. The condensation product
embedded the arsenic in a five-membered ring. The development of BAL and its ability
to detoxicate trivalent arsenicals led to the combination of a number of BAL condensa-
tion products like BAL-atoxyl, BAL-tryparsamide or BAL-stovarsol. Several of them
were tested but only one had come into general usage: Melarsoprol or Mel B.
Friedheim found melarsoprol to be 100 times less toxic than melarsen oxide and re-
ported that its trypanocidal activity was by a factor of 2.5 lower (Friedheim, 1949).
                                                                                           Fig.4 Melarsen Oxide
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                                                                                           Fig.5 Melarsoprol
Melarsoprol
From 1950 onwards melarsoprol was widely used and its effectiveness against late
stage T.b. rhodesiense infections was a major improvement (Apted, 1953). Other ad-
vantages over tryparsamide were its activity in tryparsamide resistant cases and that it
showed no toxic effect on the optic nerve (Friedheim, 1959).
Melarsoprol is effective in both, the first and the second stage of the disease, but is ex-
clusively used in the late stage because of the risk of serious adverse effects: Throm-
bophlebitis at the site of injection due to the propylene glycol solvent is frequently re-
ported. Adverse effects such as cardiotoxicity, cutaneous reactions, polyneuropathy,
diarrhea, tremors, fever, or albuminuria are quite common (Pepin, Milord et al., 1994,
Cook, 1995). A very serious complication, a drug induced encephalopathy occurs in 5-
10% of the treated patients and is characterized by fever, headache, tremor and con-
vulsions. The condition usually detoriates to deep coma within 1-2 days in 10-50% of
these patients, followed by death (WHO, 1998). The cause for this severe reaction re-
mains controversial, but generally an immunologic reaction is assumed to be involved
(Pepin and Milord, 1991, Pepin and Milord, 1994).
Ceccaldi, Director of the Pasteur Institute in Brazzaville reported a 19% fatality rate
with the remark: “of all poisons circulating in Africa Friedheim’s melarsoprol is certainly
the most poisonous one” (Friedheim and Distefano, 1989). Nevertheless, it remains the
main drug in use for treatment of late stage trypanosomiasis.
An alarmingly high incidence of treatment failures of up to 20% was lately being re-
ported from regions in Northern Angola, Northern Uganda or from the South of Sudan
(Van Nieuwenhove, 1998).
Although the drug was introduced almost half a century ago, it is not well studied yet
and its mode of action not well understood. The drug was initially thought to act by in-
hibiting the trypanosomal pyruvate kinase, which is a key enzyme in African trypano-
somes for production of ATP (Flynn and Bowman, 1974). Recent investigations showed
that trypanothion (N, N-bis-glutathionyl-spermidine), the equivalent to glutathione in Afri-
can trypanosomes and a major cofactor involved in the thiol- disulfide redox balance,
forms a stable adduct with melarsen oxide. This complex is an effective inhibitor of the
N
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trypanothione reductase, leading to disturbance of the redox balance of the parasite and
thus exposing the trypanosome to free radicals (Fairlamb, Henderson et al., 1989). How-
ever, this theory was questioned and it was suggested that the phospho-fructokinase, an
enzyme of the glycolytic pathway and interference with energy metabolism might be the
main drug target (Wang, 1995).
Three related compounds are worth mentioning melarsen oxide dithiomalate, melar-
sen oxide dimercaptosuccinate (Mel W) and its diaethylamin analogue Mel D
(Friedheim, 1959, Friedheim, 1970). Mel W and Mel D were used in therapy
(Friedheim, 1959, Nodenot, 1960) but could never replace Mel B. The reason for their
withdrawal remains unclear, since the drugs were described as water soluble, non toxic
and as effective as Mel B (especially against T.b. gambiense) (Friedheim, 1959). One
reason for their abandonment might have been the high incidence of relapses
(Robertson, 1963). Melarsen oxide dithiomalate was found to be less active than
melarsoprol, the advantages of cyclic over open chain arsenic dimercaptide structures
were discussed (Friedheim, 1951).
                                                                               Fig.6 Melarsen oxide dithiomalate
                                                                                                  Fig.7 Mel W
Further open chain derivatives like a series of dithioarsenites or p-biguanido-
phenylarsonic acids (Banks, Controulis et al., 1946) which were synthesized with the
aim of producing better soluble compounds, failed in therapy (Tillitson, 1951).
No information is available on the biological activity of a number of heterocyclic arse-
nic compounds (Mann, 1950).
Parallel to the development of the melamin arsenicals, organic arsenicals related to
phenylarsenoxide were synthesized. Gaillot and Baget prepared salts of tetracycline
antibiotics with phenylarsonate derivatives (Gaillot and Baget, 1955) and studies with
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oxophenarsine were conducted (Peters and Wright, 1943). Doak and Eagle tested a
number of phenylarsenoxides with a variety of substituents, but without structure ac-
tivity relationship of prognostic value. Most drugs were rejected because of their toxic-
ity. Only one compound, butarsen, revealed sufficient activity to be tested in man, but
it was only effective against the first stage of HAT, thus never came into general use
(Doak and Eagle, 1951).
None of the further synthesized arsenicals and also none of the antimony analogues of
melarsen oxide and Mel B replaced Mel B, although demonstrating to have similar ac-
tivity (Friedheim, 1953)
                                                                           Fig.8 Butarsen
Recent achievements
Over the past 40 years only one compound was brought to the market and approved
for use against human African trypanosomiasis: eflornithine (DFMO, ornidyl®) in 1990
(Nightingdale, 1991). It was developed originally by rational design as an antitumor
drug. Eflornithine is a specific, enzyme activated, irreversible inhibitor of the ornithine
decarboxylase (ODC). ODC catalyzes the formation of putrescine from ornithine, the
rate-limiting step in the biosynthesis of the polyamines as putrescine, spermidine and
spermine. The polyamines are essential for the growth and proliferation of prokaryotic
and eucaryotic cells (Metcalf, Bey et al., 1978). It was anticipated that an effective inhi-
bition of the ODC would stop growth in tumor cells. However, its performance in anti-
tumor trials was poor. Interestingly, it was found to have a good antitrypanosomal ac-
tivity and field trials proved that DFMO was very effective against late stage T.b. gam-
biense infections (Pepin, Milord et al., 1987). DFMO could not fulfill all hopes as the
drug is not effective in T.b. rhodesiense infections, is considerably toxic, shows a mod-
erate efficacy, a short half life and is almost unaffordable expensive.
                                                                            Fig.9 Eflornithine
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Much of the present day antiparasite chemotherapy is reminiscent of practices from the
19th century: Melarsoprol, having its empirical origin from Fowler’s solution, remains
almost a century after the introduction of Atoxylâ  the most powerful trypanocidal drug
with a capacity to cure both stages of the disease. In accordance with the few other
drugs in use, suramin, pentamidine and diminazene, it would not pass today’s drug
registration laws.
In view of the alarming increase of sleeping sickness cases and refractory cases in the
treatment with melarsoprol there is an urgent need for alternative drugs.
The ideal antitypanosomal drug must (1) be effective against both T.b. rhodesiense
and T.b. gambiense, with a large therapeutic window; (2) pass the blood brain barrier;
(3) be easy to administer, preferably without need for hospitalization of the patient; and
(4) be affordable in African countries.
However, it is well documented that new drugs are only developed when sales expec-
tations are likely to match the high costs for their development. In average, it takes six
to twelve years from the identification of an active compound to the development of a
new drug and out of 10,000 compounds synthesized only 1-2 drugs make it to the mar-
ket. Between 1976 and 1996 the cost of bringing a new drug to the market has in-
creased tenfold to more than 300 million US$ for a single drug.
Therefore, the industry has virtually abandoned large disease domains, including try-
panosomiasis, that represent huge medical needs but have no financial return (Drews
and Ryser, 1997). Two examples may illustrate this recent trend: (1) In Japan the an-
nual drug expenditure per capita is 412 US$ compared to Mozambique’s 2 US$; (2)
75% of the world’s population living in developing countries consume only 21% of the
global production of pharmaceuticals (UNDP, 1997).
Techniques used to discover a lead compound
Drug discovery is a process, which involves multiple disciplines and techniques:
         Random                              Modification of old leads
         Screening                                         or drugs
                                                            -Metabolites
                               New chemical lead               Compound for development
    New chemical idea                               New biological idea
    (Design for Target)                                          (Target)
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Random Screening
The idea of the random screening approach is to evaluate the biological activity of a
large number of compounds with a simple system in order to identify lead compounds.
The odds of finding a usable compound lie only between one in 10,000 and one in
50,000. Therefore screening is invariably associated with assays that are able to man-
age high capacities of compounds and with libraries (containing several compounds as
representatives of many structurally diverse chemicals) to facilitate the discovery proc-
ess (Hudson, 1994).
In vitro assays cannot account for pharmacological and pharmacokinetic processes
that take place in the body. The majority of current antiprotozoal drugs arose from
leads selected by in vivo assays. Such assays pose the demanding requirements of
good intrinsic activity against the target parasite coupled with appropriate pharmacoki-
netics (Hudson, 1994). In vivo assays are expensive and ethically restricted. Therefore
in vitro assays coupled with the use of human hepatocytes or microsomal incubations,
which partially mimic the metabolism in the body could serve as an alternative.
Search for drug targets
A rational approach in drug design is to undertake fundamental research on the bio-
chemical, physiological or molecular features of the parasite. A drug target has to be
unique or distinctively different from the mammalian host to allow selective inhibition,
and it must be essential for the survival of parasites. African trypanosomes are
amongst the most studied parasitic protozoa and many of their biological features have
been documented. The molecular biology of trypanosomes is unique and numerous
potential drug targets have been identified (Wang, 1995). The polyamine synthetic en-
zymes s-adenosylmethionine decarboxylase (SAMDC), ornithine decarboxylase
(ODC), which are thought to play an important role in cell division and differentiation of
trypanosomes could be targeted. Furthermore, glycolytic and purine salvage enzymes,
the trypanothione synthase and reductase, essential for the cellular defense against
oxidative stress or protein import can be viewed as attractive targets for antitrypano-
somal chemotherapy (Wang, 1995). Topoisomerases could also serve as an interest-
ing drug target: Kinetoplastid protozoa have a unique and complex type of DNA struc-
ture in the mitochondrion creating a high demand for topoisomerase activity (Englund,
Hajduk et al., 1982).
A major step towards a novel inhibitor of a target enzyme or receptor is to obtain its
three-dimensional structure, which may be investigated by X-ray or NMR spectroscopy
or computational biology based on homologous proteins of known structure. Computer
designed drugs based on the structure and function of the enzyme are selectively syn-
thesized or already known inhibitors and their binding tested (Douglas, 1994). No sin-
gle drug, however, has ever been found using a purely rational method (Spilker, 1994).
It is naïve to think that a computer designed molecule will already turn out to be the
best drug, but rational drug discovery may inspire and provide an entry point for the
Introduction                                                                                                                                   18
search. Interestingly dimercaprol comes closest to this ideal. Its synthesis was based
on a rational concept, but before the antidote was discovered 100 different compounds
were synthesized which failed in therapy (Spilker, 1994, Stocken, 1946).
Metabolic studies
Drug metabolism may also serve as a source of ideas for discovery of new com-
pounds. After application most drugs are chemically changed in the body, mainly in the
liver but also in the kidneys, lungs and other organs:
Although drugs are usually converted to less effective compounds, in some instances
the metabolites are more active than the parent compound (some metabolites may
even reveal an unexpected toxicity). A metabolite may have more desirable properties
than the parent drug and it could serve as an alternative drug or even replace the par-
ent drug (Spilker, 1994). In addition, knowledge of the metabolic pathway and the en-
zymes involved helps to avoid severe and toxic adverse effects.
Therefore pharmacological and metabolic studies play a key role in the multidisciplinary
approach of drug research and development.
The entire process from identification to marketing of an active metabolite is less com-
plex than the development of new active derivatives. Synthesis and screening activities
can be omitted and the registration of a metabolite as an additional or alternative drug
is often easier since documentation already exists (Spilker, 1994) In praxis numerous
examples are known in which drugs have been replaced by one of their metabolites or
have been improved based on the structure of their metabolites: Desmethylimipramine
is a metabolite of imipramine and both are marketed for the treatment of depression;
acetaminophen is a metabolite of phenacetin and has replaced the parent drug
(Spilker, 1994, Lambe, 1995, Park, 1986). A recent example is fexofenadin, a metabo-
lite of terfenadine, which was brought to the market in 1996. Fexofenadine has a longer
duration of action compared to terfenadine and is therefore more patient-friendly.
Moreover the metabolite lacks some of terfenadine’s adverse effects, including a fatal
tachycardia. The withdrawal of terfenadine from the U.S. market has been announced
recently (Gonzales and Estes, 1998).
Metabolic reactions of xenobiotics are generally classified into two types: Phase I reac-
tions include oxidations, reductions and hydrolysis. Oxidative alterations of molecules
are carried out by hemeproteins termed cytochromes P450. The majority of P450's in-
volved in drug metabolism appear to belong to four distinct gene families; each family
is further divided into subfamilies. Many drugs may be largely dependent on single
forms of P450 for their metabolism in the liver, because each P450 has a unique bind-
ing site. There are large differences among patients in the liver content and catalytic
activity of P450's, reflecting genetic and probably non-genetic factors. This heterogeneity
results in an individual response to the drug (Watkins, 1992).
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Phase II reactions are enzyme-catalysed conjugations of the original compound or
Phase I metabolite (provided now with a different functional group), which require the
involvement of a high energy donor substrate (Watkins, 1992).
For the study of metabolic phase I reactions subcellular fractions (microsomes) and pu-
rified enzymes (cytochrome P450) are generally used. Other systems such as intact
cells, intact organs, primary cultures, established cell lines and tissue slices are used to
study both phase I and phase II reactions (Chiu, 1993).
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Justification and aim
There is an urgent need for novel drugs for human African trypanosomiasis, which are
safe, effective and affordable. In the present study two promising strategies to discover
a lead compound for the treatment of sleeping sickness were investigated: First, re-
search on targets for intervention with inhibitors of the topoisomerase selected. Second
investigations on the metabolism of existing drugs. Melarsoprol is the current drug of
choice for late stage trypanosomiasis but its pharmacological profile has never been
studied in detail. The recently observed discrepancy between the results of two assays,
HPLC and bioassay, in determining melarsoprol concentration emphasizes the need to
carry out a thorough metabolic study for melarsoprol.
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Summary
With the use of a recently developed specific high-performance liquid chromatography
(HPLC) method and a bioassay which determines trypanocidal activity, concentrations
of melarsoprol were studied in plasma, urine and cerebrospinal fluid (CSF) from 8 pa-
tients with late stage Trypanosoma gambiense sleeping sickness. The subjects were
given their first series of melarsoprol injections- one dose i.v. per day for 4 days (1.2,
2.4, 3.0-3.6, 3.0-3.6 mg per kg b.w., respectively). Plasma samples were obtained be-
fore the first melarsoprol injection, immediately after and at 1h, 24 h and 5 days after
the 4th injection. Urine was collected before start of melarsoprol therapy and at 0-24 h
after the 4th injection. CSF samples were taken once before treatment and at 24 h after
the 4th injection. The HPLC analyses showed that the plasma concentration immedi-
ately after the 4th injection varied from 2,200 to 15,900 nmol/l, at 1 h they were consid-
erably lower, 0-1,800 nmol/l, and at 24 h no melarsoprol could be detected. In urine
small amounts of melarsoprol were recovered. Melarsoprol could not be detected in
CSF by HPLC. Immediately after injection, bioassay analyses showed plasma concen-
trations of the same magnitude as assayed by HPLC but at 1 h they were 4 to 65-fold
higher than the levels assessed by HPLC. Still at 24 h and 5 days after the 4th injec-
tion, significant but decreasing activity, could be detected. Urine levels were 40 to 260-
fold higher than the measured HPLC concentrations. In CSF low, but detectable, activ-
ity was found. The results indicate that melarsoprol is rapidly eliminated from plasma.
The significant trypanocidal activity determined by bioassay and simultaneuos low or
not detectable levels of melarsoprol assayed by HPLC, indicate that the compound is
transformed into metabolites with parasiticidal activity.
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Introduction
The arsenical melarsoprol was introduced already in 1949 for the therapy of human Af-
rican sleeping sickness and is still the main drug for treatment of late stage disease
caused by Trypanosoma rhodesiense and Trypanosoma gambiense (Pepin & Milord
1994). The efficacy of melarsoprol is high but its use is hampered both by serious ad-
verse effects, e.g. reactive encephalopathy in 4-8 % of treated patients with T. gambi-
ense (Pepin & Milord 1994) and complicated dosage regimens for repeated intrave-
nous administration. The pharmacokinetics of the drug is just preliminary characterized
due to lack of a specific analytical assay. In the only published pharmacokinetic study,
a mean elimination half life of 35 h and a volume of distribution of 100 l were found in
sleeping sickness patients (Burri et al. 1993). These calculations were based on a bio-
logical assay (Burri & Brun 1992) and atomic absorption spectrometry (Burri et al.
1993). Both methods are unspecific and cannot distinguish melarsoprol from other
substances (e.g. melarsoprol metabolites) with trypanocidal properties.
In order to be able to assess the pharmacokinetics of melarsoprol, we have recently
developed a sensitive, specific high-performance liquid chromatography (HPLC)
method (Ericsson et al. 1997) for analyses of the melarsoprol concentration in biologi-
cal fluids. We have now compared the concentrations of melarsoprol in plasma, urine
and cerebrospinal fluid (CSF) during therapy of T. gambiense sleeping sickness using
both the HPLC method and the bioassay, with the aim to unravel to what extent the
bioassay codetermines biologically active metabolites of melarsoprol.
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Patients and Methods
Patients
Eight consecutive patients with T. gambiense disease at the national research centre
for trypanosomiasis (P.R.C.T.) in Daloa, Côte d’Ivoire, were included. Examination of
peripheral blood using the mini-anion exchange centrifugation technique (Lumsden et
al. 1979) demonstrated trypanosomes in all subjects. In four patients double centrifu-
gation of CSF showed parasites and the remaining four had an increased CSF white
cell count (median 253, range 36-954 x 106/l). Thus, the eight subjects were consid-
ered to suffer from late stage disease according to the WHO criteria (WHO 1986).
The median age was 26 (range 10-36) years and the median weight was 56 (range 24-
61) kg. Four patients were females.
Study design
The subjects were given one daily intravenous dose of melarsoprol (Arsobal®, Specia,
Paris France) for 4 days (1.2, 2.4, 3.0-3.6, 3.0-3.6 mg per kg b.w. respectively), which
constituted the first of three series of melarsoprol injections. The daily dose never ex-
ceeded 180 mg melarsoprol as this dosage was considered to be the maximum dose
at the centre. Between two and five days before the first melarsoprol injection, the pa-
tients received one dose of 4 mg pentamidine isethionate (Pentacarinat®, May &
Baker, Rhône-Poulenc Rorer, Dagenham, England) per kg b.w. intramuscularly as well
as a single dose of 0.5 mg betamethasone intramuscularly (Diprostene®, Schering-
Plough, Levallois-Perret, France). Pentamidine was given in order to kill parasites in
peripheral blood and betamethasone as prophylaxis against encephalopathy, accord-
ing to the routine at centre.
Plasma samples were obtained before the 1st melarsoprol injection, immediately after
and at 1 h, 24 h and 5 days after the 4th injection by separate venepunctures. Urine
was collected during 24 h before the 1st melarsoprol injection and during 0-24 h after
the 4th melarsoprol injection. CSF samples were obtained by lumbar puncture before
the 1st melarsoprol injection and at 24 h after the 4th injection.
The study design was approved by the Ministry of Health, Abidjan, Côte d´Ivoire. All
subjects or accompanying relatives gave verbal consent to the study after explanation
of the protocol.
Handling of samples
Blood was collected in 4.5 ml Vacutainer tubes containing ethylene diaminetetraacetic
acid (EDTA) and centrifuged within 15 min in a Beckman refrigerated centrifuge
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(Beckman Instruments, Palo Alto, USA) at 1000 g for 10 min. The plasma was trans-
ferred to a NUNC® tube (InterMED, Roskilde, Denmark) and frozen at -196o C within a
few minutes. Urine was collected in 2.5 L plastic (high-density polyethylene) containers
(LAGAN-plast, Ljungby, Sweden), the volume was measured and 5 ml aliquots were
transferred to two NUNC® tubes and frozen as above.
CSF was collected directly in NUNC® tubes and frozen as previously described.
The plasma, urine and CSF samples were kept frozen at -196o C in Africa, in dry ice
during 24 h of transportation to Europe, and at -70o C in Europe pending assay.
Drug analyses
HPLC
The HPLC assay consists of a reversed-phase liquid chromatography system with UV
detection recently described by us (Ericsson et al. 1997). The lower limit of determina-
tion is 9 nmol/L, 45 nmol/L and 10 nmol/L, in plasma, urine and CSF respectively, with
a coeffecient of variation of 3-6%. All samples were analyzed in duplicates. 100-
1,000 µl of plasma, urine or CSF were used per assay.
Bioassay
The bioassay determines parasiticidal activity in different body fluids using a T. rhode-
siense in vitro model. The lower limit of determination is 22.6 nmol/l with a coeffecient
of variation of 20% (Burri & Brun 1992). All determinations were made in triplicates with
a sampling volume of 100 µl per assay.
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Results
HPLC
Immediately after the 4th injection, the plasma melarsoprol concentrations varied be-
tween 2,230 and 15,900 nmol/l, at 1 h after dose they were considerably lower (0-
1,780 nmol/l) and at 24 h and 5 days no melarsoprol could be detected (Table 1). In
urine low concentrations (0-3,680 nmol/l) were recovered. The compound could not be
detected in CSF (Table 2).
Bioassay
The plasma concentrations immediately after the 4th injection were similar to levels as-
sessed by HPLC but at 1 h they were 4 to 65-fold (median 25-fold) higher. Still at 24 h
and 5 days after the 4th melarsoprol injection, significant but decreasing activity could
be detected (Table 1).
Urine levels were 40 to 260-fold (median 180-fold) higher than the measured HPLC
concentrations. In CSF low, but detectable, activity was found (Table 2).
Before the 1st melarsoprol injection, low levels of trypanocidal activity could be deter-
mined by the bioassay in plasma in all subjetcs (Table 1). In urine and CSF, low levels
were also recorded before the first injection in 6 and 3 patients, respectively (Table 2).
The marked difference between HPLC and bioassay determinations in plasma is
clearly visualised in Fig. 1 (patient no. 5).
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Discussion
The results of the present study demonstrate that melarsoprol is rapidly eliminated from
plasma, i.e. within hours. As the number of sampling points were few, we were not able
to calculate pharmacokinetic parameters but it is obvious that the elimination half life is
much shorter than the 35 h previously reported.
Substantially lower levels of melarsoprol were determined in urine by HPLC compared
to the bioassay. However, melarsoprol is not stable in urine at room temperature (Er-
icsson et al. 1997) and it is therefore not possible to determine the true concentration of
melarsoprol in urine by HPLC since the urine was collected at the ward during 24 h.
The low trypanocidal activity detected by bioassay in plasma and CSF before the first
melarsoprol injection is probably due to pentamidine still present in these body fluids,
an observation explained by its pronounced tissue affinity and very slow elimination
from the body (Bronner et al. 1995).
The trypanocidal activity measured in the pretreatment urine samples of patients no. 1,
7 and 8, was considerable and probably also a result of the pentamidine injected 2 to 5
days before melarsoprol.
In addition, patient no. 8 received a few doses of metronidazol 4 days before the 1st
melarsoprol injection for therapy of an amoeba-infection. Metronidazol is reported to
have clinical effect in the therapy of T. rhodesiense sleeping sickness (Foulkes 1996)
and may therefore induce trypanocidal activity in the samples from this patient.
The significant trypanocidal activity determined by bioassay in plasma, urine and CSF
and simultaneous low or not detectable levels of melarsoprol assayed by HPLC, indi-
cate that melarsoprol is eliminated from plasma by transformation into metabolites with
parasiticidal activity.
No melarsoprol was detected in CSF 24 h after the 4th injection while the bioassay
showed low trypanocidal activity. This finding may also be explained by the presence of
active melarsoprol metabolites.
The metabolic fate of melarsoprol is unknown but there are several ways by which
melarsoprol can be transformed. A possible metabolite is melarsen oxide, which also
can be formed from melarsoprol by non-enzymatic hydrolysis (unpublished data from
our laboratories). It has trypanocidal activity and has been used in the therapy of Afri-
can sleeping sickness (Friedheim 1948) but was abandoned because of its toxicity.
Melarsoprol was originally synthesized by reacting melarsen oxide with BAL (William-
son 1970), and it was believed but not verified in comparative trials, that melarsoprol
was less toxic than melarsen oxide.
Other possible metabolic pathways include N-oxidation, aromatic or aliphatic oxidation,
and direct conjugation.
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The ordinary treatment schedule for therapy with melarsoprol - 3-4 series of 3-4 injec-
tions with an interval of 7-10 days between the series- has been used for many years
and is still advocated by the WHO (WHO 1986). A fear of drug accumulation has moti-
vated the long drug-free intervals. However, investigations have not yielded any signs
of drug accumulation (Cristau et al. 1975; Burri et al. 1994), and this complicated dos-
age schedule was recently questioned on the basis of new pharmacokinetic information
mainly obtained by the bioassay method and computer simulations. An alternative
schedule, consisting of ten daily doses of melarsoprol, was proposed (Burri et al. 1993)
and has been successfully tested on 11 patients in Zaire (Burri et al. 1995).
The present finding of a rapid plasma elimination of melarsoprol and sustained try-
panocidal activity in plasma and CSF probably caused by metabolites, clearly shows
the need to use the bioassay when designing new treatment schedules. It is also obvi-
ous that the use of chromatographic techniques is crucial when trying to reveal active
metabolites of melarsoprol.
Despite the introduction of eflornithine (DFMO) in the treatment of sleeping sickness
(Bacchi et al. 1983; Van Nieuwenhove et al. 1985; Doua et al. 1987), melarsoprol is the
only drug available for the majority of patients suffering from T. gambiense and T. rho-
desiense sleeping sickness with CNS involvement. Thus, the improvement of its use is
still of clinical relevance. The encephalopathy induced by this drug is of major clinical
concern and the most important complication of melarsoprol treatment. Its etiology has
not been elucidated and the role of metabolism in the disposition of melarsoprol has
just been discovered. It can be hypothezised that melarsoprol is transformed into para-
siticidal metabolites with more or less toxic properties. Further studies on the disposi-
tion and metabolism of melarsoprol are needed as they may shed light on the issue of
melarsoprol toxicity and be very valuable when reevaluating the dosage regimen of this
drug.
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Figure 1
Plasma concentrations of melarsoprol 0-120 h after the 4th i.v. injection of 1.2-3.2 mg
melarsoprol per kg b.w. in patient no. 5. Analyses by HPLC and bioassay of the same
samples are shown.
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Melarsoprol concentrations in plasma determined by HPLC and bioassay in 8 patients with T. gambiense sleeping sickness ad-
ministered 4 i.v. injections of 1.2- 3.6 mg melarsoprol per kg b.w.
Before 1st injection Immediately after 4th
injection
1h after 4th injection 24h after 4th injection 5d after 4th injection
HPLC bioassay HPLC bioassay HPLC bioassay HPLC bioassay HPLC bioassay
0 590 5500 11300 200 13160 0 9040 0 980
0 45 2230 9040 1780 6570 0 1790 0 280
0 45 8250 8380 310 9040 0 4550 0 720
0 90 ND ND ND ND 0 3240 0 480
0 90 15900 15010 290 6040 0 4520 0 1300
0 1080 4400 9040 290 6390 0 4520 0 510
0 90 8900 10300 220 7530 0 3940 0 530
0 70 6180 8280 0 7750 0 2260 0 580
Melarsoprol concentrations in urine and CSF determined by HPLC and bioassay in 8 patients with T.
gambiense sleeping sickness administered 4 i.v. injections of 1.2- 3.6 mg melarsoprol per kg b.w.
                                    Urine                                                                          CSF
0-24h before 1st injec-
tion
0-24h after 4th injec-
tion
Before 1st injection 24h after 4th injection
HPLC bioassay HPLC bioassay HPLC bioassay HPLC bioassay
0 12340 1280 139800 0 0 0 90
0 720 0 7230 0 0 ND 80
0 180 3680 139800 0 0 0 100
0 0 ND ND ND 0 0 140
0 100 1020 101230 0 10 ND 140
0 0 380 23470 0 50 0 80
0 7670 990 130150 0 0 0 45
0 17470 450 115690 0 20 0 180
ND= not determined
The subjects were also given a single i.m. injection of 4 mg pentamidine isethionate 2-5 days before the first dose of melarsoprol.
Physico-chemical properties of the trypanocidal drug melarsoprol                                                39
Physico-chemical properties of the trypanocidal drug mela rsprol
J. Keiser, C. Burri
Swiss Tropical Institute, Department of Medical Parasitology and Infection Biology, P.O. Box,
CH-4002 Basel, Switzerland
Keywords: Melarsoprol, protein binding, Trypanosomiasis, Sleeping sickness
Published in Acta Tropica 74 (2000) 101-104
Physico-chemical properties of the trypanocidal drug melarsoprol                                                40
Introduction
Trypanosomiasis is a communicable disease, caused by the protozoan parasites Try-
panosoma brucei gambiense and T.b. rhodesiense. 55 million people in 36 African
countries are at risk of the disease. The recent epidemic outbreaks affecting several
regions with about 300 000 new cases annually (Smith et al., 1998) reinforces the need
for efficient, safe and affordable drugs, or as a minimal temporary requirement the im-
proved application of the existing ones.
Melarsoprol (Arsobal®) remains the drug of choice for the treatment of the late stage of
sleeping sickness, in which the parasite has invaded the central nervous system. The
only new compound, eflornithine, which has been introduced during the last 50 years,
is hampered by its almost unaffordable costs, its ineffectiveness against T.b. rhodesi-
ense, and the short duration of action and low efficacy which cause logistic problems.
Though melarsoprol was introduced in 1949 (Friedheim, 1949) remarkably little is
known about the mechanism of action (Fairlamb et al., 1989, Wang, 1995), and only
limited data on its chemical, pharmacological and pharmacokinetic properties are
available (Cristau et al., 1975, Pepin and Milord, 1994, Burri et al., 1993, Burri et al.,
1994). The drug is administered by intravenous injection as a 3.6% solution in propyl-
ene glycol. Adverse drug reactions like cutaneous reactions, polyneuropathy, diarrhea,
fever or thrombophlebitis at the site of injection (Pepin and Milord, 1994, Molyneux et
al., 1996) are quite common. Encephalopathic syndromes, which are reported to occur
in 2-10% and being fatal in 50-70%, are the most important complication of melarsoprol
treatment. Its trigger remains controversial, but immune reactions are suggested
(Hunter et al., 1992, Haller et al., 1986).
Plasma protein binding has a significant impact on the clinical pharmacology and
pharmacokinetics of a drug, since normally only the unbound moiety is available for
distribution, elimination and drug action (Wright et al., 1996). Displacement of the drug
from its protein binding is often responsible for drug interaction related adverse effects
(Tillement et al., 1984). The lipid solubility and dissociation constant are two other im-
portant physical parameters. As lipoid membranes, like the blood brain barrier, can only
be passed by lipid soluble and unionized molecules these parameters essentially influ-
ence the pharmacokinetics of the drug (Brodie et al., 1960). Since late stage of try-
panosomiasis is characterized by the invasion of the parasites into the CSF, penetra-
tion of the blood brain barrier is a fundamental requirement for successful treatment.
The melarsoprol levels in the CSF are about 50 times lower than those in serum (Burri
et al., 1993) which may be due to ionization or a strong protein binding of drug.
To elucidate essential basic pharmacological properties of the drug we studied the
protein binding, the water / octanol coefficient of partition (P) and the dissociation con-
stant (pKb) of melarsoprol, as well as of one of its suggested metabolites melarsen ox-
ide (Bronner et al., 1998).
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Methods and results
Drugs and Chemicals
Melarsen oxide was obtained from Rhône-Mérieux, Laboratoire de Toulouse, France;
melarsoprol was purchased (Arsobalâ , batch 701) from Specia, France. Solvents and
chemicals were purchased from Merck.
Chromatographic system
Peak areas were determined with a chromatographic system consisting of Waters
pump 510 (flow 1 ml/min), an ultraviolet detector Spectroflow 773 Kratos and a Spectra
Physics SP 4270 integrator equipped with a Beckman RP-C18 ODS ultrasphere (5 mm,
4.4 mm I.D.* 15 cm) column and a C18 guard column (5 mm, 4.6 mm I.D.* 4.5 cm). The
detection wavelength were for melarsen oxide 274 nm and for melarsoprol 283 nm.
The mobile phase consisted of 4 ml of acetonitrile and 96ml of distilled water (HPLC
quality) for melarsen oxide and 25 ml of acetonitrile and 75 ml of water for melarsoprol.
Determination of the coefficient of partition P
The partition of melarsoprol and melarsen oxide between buffer and n-octanol was
analyzed with the shake flask method at physiological pH (Leo et al., 1971, Pöyhiä and
Seppälä, 1994): For melarsenoxide 5 ml n-octanol was added to 5 ml of a 6 mM solu-
tion of melarsen oxide in 0.1 M ammonium acetate buffer adjusted with 1 M NaOH to
pH 7.4 in five test tubes each. A more lipophilic characteristic was predicted for melar-
soprol, which made necessary an increased assay concentration to prevent levels in
the water phase below the limit of detection. A maximum of 180 mM was achievable,
limited by the poor water solubility of the compound.
The tubes were incubated for 1 hour in a rotation mixer at 22°C. For determination of P
(Cpre-Cpost/Cpost) 20 ml of the aqueous phase was injected into the HPLC and the con-
centration calculated according to the areas.
The average value of P for melarsen oxide was determined as 8.4.
For melarsoprol the coefficient of partition between buffer and n- octanol was calcu-
lated of approximately 160. The exact value could not be determined due to the poor
water solubility of the compound. The P value was previously determined spectrometri-
cally to be 40 at pH 7 for melarsoprol (Cristau et al., 1972), which corresponds to the
value of 160 determined at pH 7.4.
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Analysis of protein binding
The binding of melarsoprol and melarsen oxide to serum proteins, e.g. albumin (35 g/l),
and a-1-acid glycoprotein (0.55 g/l) was studied based on a physical separation by ul-
trafiltration (Pöyhiä and Seppälä, 1994, Wright et al., 1996). Prior to the experiment the
occurrence of binding of the drug to the filter Centrex UF-0.5 (10000 kDa Schleicher &
Schuell filters) was tested and could be excluded.
The protein solutions were spiked with 18 mM melarsoprol, which corresponds to thera-
peutic concentrations found in samples of human patients (Ericsson et al., 1997) and
3 mM melarsen oxide. The samples were incubated for 30 minutes at 37°C in eppen-
dorf tubes. The unbound drug was then separated by centrifugation at 12000g. The
concentration of the free drug in the filtrate was determined by high performance liquid
chromatography as described and the binding was calculated according to cbound= cprae-
cpost. For each binding experiment the procedure was repeated five times.
For melarsoprol a total serum protein binding of 79%, an albumin binding of 79% and a
glycoprotein binding of 70% was calculated. The total serum protein binding of melar-
sen oxide solution was 72%, the binding to albumin 46% and to a-1-acid glycoprotein
37%.
Ionization constant
The protonation constant was determined potentiometrically: 25 ml of a 0.9 mM melar-
soprol solution and of a 1.1 mM melarsen oxide solution in water were pre-acidified to
pH 2.2 - 2.9 with 1 M HCl and were then titrated alkalimetrically with 1 mM NaOH to a
high pH. Three titrations were carried out for each drug at room temperature, the pKa
values of the corresponding acids were calculated with the Henderson-Hasselbalch
equation (Latscha and Klein, 1990).
The pKa was calculated as 4.8, the corresponding pKb 9.2 for melarsoprol and the pKa
4.5 and pKb 9.5 for melarsen oxide, respectively.
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Discussion
The lipid solubility of the unionized drug molecule is the physical property largely gov-
erning the rate of entry into the CSF (Brodie et al., 1960). The P values calculated for
melarsenoxide and especially melarsoprol indicate a high lipophilicity. However, for
highly ionized drugs, a relationship exists between the degree of ionization and the
CSF permeability constant; completely ionized compounds like sulfosalicylic acid
hardly penetrate into the CSF, partially unionized molecules as for example salicylic
acid have a permeability constant, roughly relating to the proportion of unionized drug
(Brodie et al., 1960). At a physiologic pH of 7.4 only a small quantity of both com-
pounds is unionized (0.2% of melarsoprol and 0.1% of melarsenoxide), and thus only a
small amount of drug is available to cross lipoid membranes.
The results obtained are supported by the earlier finding that the CSF concentrations
are very low compared to the plasma levels in samples of patients treated with melar-
soprol. The levels found in the serum were in the range of 1.5 - 2 µg/ml after the fourth
injection of each therapy course, whereas the levels measured in the CSF at the same
time were about 50 times lower (mean in the range of 30 ng/ml determined by bioas-
say) and in one third of the patients the concentrations were below the limit of detection
of 9 ng/ml (Burri et al., 1993).
Drugs with a protein binding of 50 to 85% are considered medium binding drugs (Klotz,
1984., Wright et al., 1996). The extent of the protein binding of both compounds may
be responsible, together with the ionization constant, for the slow CSF concentration
adaptation of melarsoprol and its potential metabolites (Burri et al., 1993, Burri et al.,
1994, Bronner et al., 1998). Only a small fraction of the drug is available to add to the
concentration gradient which drives the distribution into CSF.
The in vivo situation might be more complicated: Large interindividual variability of drug
levels is a common feature (Rowland and Tozer, 1989). Sleeping sickness patients of-
ten have elevated IgG or IgM levels (Molyneux et al., 1996), which may result in an in-
creased total protein binding. Concomitant diseases like malaria, hepatitis and mal-
nourishment (Wright et al., 1996) may cause a modification of the plasma concentra-
tions of albumin and a-1-acid glycoprotein. For melarsoprol up to 10-fold concentration
differences were determined by a biological assay at equal timepoints in serum and in
CSF (Burri et al., 1993). These interindividual differences combined with the low thera-
peutic index may provide a partial explanation of the distribution of adverse effects fre-
quently seen in the therapy with the arsenical drugs. A decreased level of bound drug
may result in an increase of toxic effects, because of the resulting elevated levels in
compartments and tissues otherwise poorly reached. The metabolic pathway of melar-
soprol is largely unknown and differences in the individual metabolic capacity of pa-
tients may further complicate the situation. In order to better understand the adverse
events compromising the use of melarsoprol it would be interesting to elucidate the
metabolic pathway and to conduct more detailed pharmacokinetic studies.
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Abstract
Background Melarsoprol (Arsobal®) remains the first choice drug for trypanosomiasis
(Human African sleeping sickness). To contribute to the sparse pharmacological data
and to better understand the etiology of the frequent serious adverse reactions we
have investigated the metabolism of this 50 years old organoarsenic compound.
Findings The half life of melarsoprol was < 1 h (HPLC), compared to 35 hours by bio-
assay and atomic absorption spectroscopy (AAS) indicating the existence of active
metabolites. One metabolite, melarsen oxide, was identified by HPLC-UV after incuba-
tion of melarsoprol with microsomes. The metabolite is mainly formed by hydrolysis
and not enzymatically. In humans cmax of melarsenoxide was reached 15 min after ap-
plication, the clearance was 21.5 ml/min/kg and the half life of free melarsen oxide was
3.9 h. Either melarsen oxide, or a yet undiscovered further active metabolite, is irre-
versibly bound to proteins as shown by ultrafiltration, precipitation experiments and
AAS. Due to the poor pharmaceutical properties of melarsoprol the therapeutic poten-
tial of melarsen oxide was investigated. In an acute infection rodent model 20/20 mice
were cured (0.1-1 mg/kg i.v. or 2.2 mg/kg i.p.). In a CNS infection rodent model 5/6
mice survived for more than 180 days (5 mg/kg i.v), indicating a sufficient melarsen
oxide penetration across the blood brain barrier.
Interpretation The perspectives for the future of trypanosomiasis treatment are de-
plorable. Therefore pharmacological investigations to improve the use of the first line
drug melarsoprol are required. The presented results may build a basis for further re-
search on the etiology of severe adverse reactions.
Keywords: Melarsoprol, Melarsen oxide, metabolites, Trypanosomiasis, Sleeping
sickness, HPLC, bioassay, AAS, covalent binding, drug metabolism
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Introduction
Sleeping sickness (Human African Trypanosomiasis) is caused by Trypanosoma brucei
sp., kinetoplast parasites, transmitted by the bite of the tsetse fly (Glossina sp.). The
disease is found over vast areas of sub-Saharan Africa and exists in two clinical forms:
The West and Central African form (T. brucei gambiense) is a chronic disease, which
continuously aggravates over several years, before death occurs, while the East Afri-
can form (T. brucei rhodesiense) develops acutely. The onset of the disease is unchar-
acteristic with fever and general malaise. In the second stage, after invasion of the
central nervous system by the parasite, severe mental and endocrinic disturbances like
delirium, mania, paranoia, schizoid attacks, aggressive behaviour and severe motor
problems are the main signs. Without appropriate treatment both forms of the dis-
easeare fatal 1.
An estimated 55-60 million of people are at risk of becoming infected with trypano-
somes, but only four million of them are under active surveillance or have access to
health centres where reliable diagnosis and treatment is available 2. While the disease
had been brought under control at the end of the 1960’s, the situation has deteriorated
since 1970 and major outbreaks are reported from countries like the Democratic Re-
public of Congo, Angola and Sudan 3. The number of infected persons is currently es-
timated at over 300’000 2.
Chemotherapy has made very little progress over many decades: the main drugs for
the treatment of the first stage of disease are suramin and pentamidine, introduced
1922 and 1941. Due to a lack of valid alternatives the treatment of the second stage is
mainly realised by the organoarsenic drug melarsoprol [p-(4,6-diamino-S-triazinyl-2-yl)-
aminophenylarsenoxide]-2,3-dimercaptopropanol (Arsobal®) introduced in 1949 4. The
drug is administered by intravenous injection as a 3.6% solution in propylene glycol.
Adverse effects like cutaneous reactions, polyneuropathy, diarrhoea, fever or thrombo-
phlebitis at the site of injection are quite common 5,6. Encephalopathic syndromes are
the most important complication of melarsoprol treatment, and occur at a rate of 5-10%
and are fatal in 10-50% 2. The trigger of the encephalopathies remains controversial,
but immune reactions are suggested 7,8.
Only one drug, eflornithine (a-difluoromethylornithine), was brought to the market in the
last decade 9. However, the compound is only active against T.b. gambiense and is
almost unaffordably expensive 2.
Despite the long utilisation, remarkably little is known on the chemical, pharmacological
and pharmacokinetic properties of melarsoprol 5,10-12. Recent results indicate that
melarsoprol is metabolised to one or several active products. A terminal half life of 35
hours was determined by a biological assay, while the corresponding parameter de-
termined by a HPLC method was 1 hour. The bioassay measures overall trypanocidal
activity, whereas melarsoprol is specifically detected by HPLC 13.
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Metabolites often have pharmacological properties different from their parent drugs and
may be responsible for the activity of a drug as well as for adverse effects 14. Hence,
the metabolic pathway of melarsoprol was studied to get a better knowledge of the
drug and to better understand the nature of the serious adverse effects related to its
use.
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Material and Methods:
Chemicals
Melarsen oxide was obtained from Rhone-Mérieux, Laboratoire de Toulouse; melarso-
prol (Arsobalâ , batch 701) was purchased from Specia, France. All solvents and
chemicals were purchased from Merck (analytical quality).
Biological samples
Blood and cerebrospinal fluid (CSF) samples were obtained from five T.b. gambiense
infected patients treated with melarsoprol at the Trypanosomiasis Reference Centre of
Viana, Angola. The baseline characteristics of the patients are given in table I. The pa-
tients received 10 x 2.2 mg/kg of melarsoprol spaced by 24 h according to the protocol
of Burri 11: To investigate the nature of the metabolites and to determine their pharma-
cokinetic properties, serum was collected by venepuncture before, and 15 min, 1, 3, 6,
8 and 24 h after the first drug application. CSF was obtained by spinal tap from two pa-
tients at 1 and 6 h respectively, and from one patient at 24 h after the first drug applica-
tion. In addition, to determine the level of metabolites at the end of treatment, samples
collected 24, 48 and 72 h after the third course of melarsoprol injection were used.
Those samples were collected for pharmacokinetic investigations at the Projet de Re-
cherches Cliniques sur la Trypanosomiase, PRCT, Daloa, Ivory Coast in 1990 11. All
samples were frozen and shipped on dry ice or in liquid nitrogen to the Swiss Tropical
Institute, where they were stored at – 80°C. The chosen storage conditions of the sam-
ples were evaluated by accelerated stability tests.
Analytical procedure for the incubation of microsomes
Microsomes were prepared from pooled human liver samples. The protein content was
measured as described by Lowry 15. The microsomes were incubated at 37 °C with a
50 µM or 100 µM solution of melarsoprol in the presence of 2 mM NaDPH, 2.5 mM
MgCl2 and 50 mM TrisHCl for 30 min. The reaction was terminated with 0.05 M zinc
sulphate in 50% v/v acetonitrile or with 100% methanol. All reactions were performed in
triplicates, and samples without NaDPH or drug served as controls. After centrifugation
for 10 min at 3000g the supernatant was evaporated under a stream of nitrogen and
the pellet reconstituted in acetonitrile/distilled water (1:1 v/v) and analysed by HPLC-
UV. Isocratic runs were performed using a mobile phase of 0, 2, 4, 8, 12, 20 and 30 ml
of acetonitrile with distilled HPLC water (to a total of 100 ml) in order to detect all prod-
ucts at satisfactory retention times according to their polarity.
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High performance liquid chromatography (HPLC) for the determination of melar-
sen oxide
The HPLC system consisted of a Waters pump 510 (flow 1 ml/min), a Beckman RP-C18
Ultrasphere ODS column with 5 mm particle size (4.4 mm I.D.* 15 cm length) with a C18
guard precolumn (4.4 mm I.D.* 4.5 cm length), an ultraviolet detector Spectroflow 773
(Kratos) and a Spectra Physics 4270 integrator. The isocratic mobile phase consisted
of 4 ml acetonitrile and 96 ml distilled water of HPLC quality. The detection wavelenght
for melarsen oxide was 274 nm and the peak areas were measured. The limit of de-
termination was 16 ng/ml.
Determination of melarsen oxide in serum and CSF samples
100 - 1000 ml of serum or CSF were pipetted into 12 ml polypropylene tubes and 200 -
2000 µl 0.05 M zinc sulphate in 50% v/v water/acetonitrile were added for precipitation
of the serum proteins. After mixing for 10 sec using a vortex mixer the samples were
allowed to stand for 10 min. The tubes were then centrifuged for 10 min at 3500g. The
supernatant was transferred to a new test tube, evaporated gently to 20 - 50 µl under a
stream of nitrogen and directly injected into the chromatographic system. All samples
were assayed in duplicates. Standard curves were prepared by adding known amounts
of melarsen oxide to drug free serum and the samples treated as described above. The
resulting peak areas were plotted versus concentration. The limit of quantification was
50 ng/ml (R.S.D: 7.9%). No peak interference with quinine, pentamidine, phenobarbital
or chloroquine was observed.
In human samples melarsen oxide was identified by retention time and in vitro confir-
mation of the activity of the fraction containing the respective peak. The fraction was
evaporated under nitrogen, dissolved in sterile distilled water and the trypanocidal ac-
tivity tested following the method described by Räz 16.
Determination of melarsoprol with HPLC
Melarsoprol concentrations in serum and CSF were determined using a previously de-
scribed method 17.
Determination of the binding of active products to serum proteins
1 ml of human serum collected at least 24 h after the last injection of melarsoprol was
pipetted into test tubes and an equal amount of precipitating solvents added. The fol-
lowing solvents were tested: 0.05 M zinc sulphate in 50% v/v water/acetonitrile, b-
mercaptoethanol, DMSO, 7 M NaOH, tri-chlor-acetic acid (TCA) and proteinase K. Af-
ter mixing for 10 sec on a vortex, the samples were allowed to stand for 10 min at room
temperature. Then they were centrifuged at 3000g and the supernatant and the protein
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pellet were separated. Both phases were analysed by atomic absorption spectroscopy
(AAS). In one additional experiment the protein pellet was boiled with 1 M KOH at 80°C
for 1 h and the supernatant was examined by AAS.
For the analysis of active components bound to proteins in the CSF a total of 7 ml was
pooled from 3 patients in a test tube and 0.05 M zinc sulphate in 50% v/v wa-
ter/acetonitrile were added. After centrifugation at 3000g for ten min the supernatant
was discarded, and the pellet was analysed by AAS.
For ultrafiltration 1 ml of human serum sampled either 24, 48 or 72 h after the last in-
jection of melarsoprol was centrifuged at 10’000g for 15 min in tubes equipped with
Centrisart I (Sartorius) filters of either 5 kD, 10 kD and 20 kD or 100 kD cut off. The ac-
tivity of the filtrate and of the residue was analysed by bioassay.
Determination of the irreversible binding of melarsen oxide to macromolecules
6 mM of melarsen oxide were incubated in blank human serum for 48 h at 37 °C. The
serum proteins were precipitated with equal amounts of 0.05 M zinc sulphate in 50%
water/acetonitrile v/v. After vortexing the sample and centrifugation at 3000g the arse-
nic content of the protein pellet was determined by AAS. The same experiment was
conducted in presence of 5 mM of the thiol blocking agent p-hydroxymercuribenzoate,
to test whether melarsen oxide is bound to a sulphur group of plasma proteins.
Determination of arsenic in serum, urine and CSF by atomic absorption spec-
troscopy
Electro thermal atomic absorption spectroscopy (AAS) for determination of the arsenic
content of the samples was performed on a Varian AA-400 Zeemann equipped with a
graphite furnace operated at 193.7 nm, by Amt für Umwelt und Energie, Basel. The
material was mineralised in a microwave oven with 2 ml 65% HNO3 and 2 ml hydrogen
peroxide 30% at 150 W for 10 min. All samples were assayed in duplicates. Three
spiked control samples for AAS determination were prepared at concentrations of
1440, 3600 and 7200 ng/ml of melarsoprol. In the first spike 1510 ng/ml or 111% of the
arsenic in the other two samples 103% and 85% of the arsenic was recovered. The
limit of determination was 50 ng/ml of arsenic using a 250 µl specimen and the RSD
was 1.6%.
In vitro activity testing and bioassay determination of drug levels
The trypanosome clone STIB 900, a cloned derivative of T.b. rhodesiense STIB 704,
isolated 1982 in Tanzania, was used for in vitro growth inhibition studies. Bloodstream
forms were cultured in Minimum Essential Medium (MEM) with Earle’s salts (powder,
GIBCO/BRL No.072-01100 P) supplemented with 25 mM HEPES, 1 g/l additional glu-
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cose, 2.2 g/l NaHCO3 and 10 ml/l MEM nonessential amino acids (100x). The medium
was further supplemented according to Baltz 18.
To test the activity of melarsoprol metabolites the Alamar Blue® assay was used as
previously described 16. The tested maximum concentration for all substances was
100 µg/ml. Stock solutions in dimethyloxide (DMSO) were prepared and diluted with
culture medium. Bloodstream forms of T.b. rhodesiense were inoculated into 96-well
microtiter plates (Costar, USA). The trypanosomes were incubated with serial drug di-
lutions for 70 h at 37 °C in 5% CO2. Then 10 ml Alamar Blue® were added and after 2 h
of incubation the fluorescence at an excitation wavelength of 530 nm and an emission
wavelength of 590 nm determined. The IC50 values were calculated by linear interpola-
tion 19.
For determination of the total trypanocidal activity of biological fluids, calculated as
melarsoprol equivalents, a modification of the Alamar Blue® assays with a limit of de-
termination of 4 ng/ml was used 20. For determination by bioassay 100 µl of the patient
sample were required.
In vivo testing of activity
Acute rodent model
Animals: Female CD1 mice (20 - 25g) were purchased from Charles River, Germany.
Groups of five animals were used; animals were infected intraperitoneally with 2*105
trypanosomes of STIB 704. Treatment was started 24 h after infection. On four con-
secutive days, several doses of the drug were administered intraperitoneally and intra-
venously. One control group without treatment was included in the experiment. Animals
were checked twice a week for parasites in tail vein blood. Animals surviving >30 days
were considered as cured.
Relapse infection rodent model
The ability of melarsen oxide to pass the blood brain barrier and its curative effective-
ness in the central nervous system were also examined in the TREU 667 second stage
CNS model infection 21. Mice were infected with 106 parasites. After 21 days of devel-
opment of the infection mice were treated with 5 mg/kg of intravenous melarsen oxide
for seven days. After the end of treatment mice were checked weekly for parasites, and
they were considered to be cured if they survived for at least 180 days. A group of mice
obtaining once 40 mg/kg Berenil served as control. Berenil does not pass the blood
brain barrier. The drug clears the trypanosomes from the circulation and organs other
than the brain.
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Results
Microsomal study
Melarsen oxide was the only product that could be detected by HPLC analysis after mi-
crosomal incubation followed by precipitation. The peak was identified by comparison
of the retention time with a melarsen oxide solution. Melarsen oxide could also be de-
tected at the same concentration range in the control run without NaDPH. This indi-
cates that melarsen oxide is not formed in a microsomal reaction but by hydrolysis.
Whether melarsen oxide is also formed enzymatically to a limited extent can not be
concluded from this experiment.
Concentration- time profile of melarsen oxide in serum
The pharmacokinetic profile of melarsen oxide was investigated by HPLC in five T.b.
gambiense patients after application the first of ten doses of 2.2 mg/kg of melarsoprol
(table II).
The maximum levels (Cmax) of melarsen oxide ranged from 461 to 848 ng/ml (average
636 ± 157) and were detected 15 min after drug administration (Table III). Within 8 h
they fell to 7-11% of Cmax and thereafter a half-life of 3.9 h (s = 0.7) accounted for the
area under the concentration time curve. The average clearance was calculated as
21.5 (s = 3.3) ml/min*kg. (The calculation of t1/2 and CL was based on the value of pa-
tients one to four due to outlier results). In samples taken 24 h after the first application
the melarsen oxide concentrations were below the limit of quantification of 50 ng/ml
(Table III).
To confirm the melarsen oxide levels, serum samples previously collected from eight
patients 13 receiving the fourth injection (first series) of melarsoprol were analyzed.
Cmax were reached five min after application and ranged from 758 to 2371 (average
1147) ng/ml. After 1 h 247-889 (average 640) ng/ml could be detected, in samples
taken 24 h after injection the levels of melarsen oxide were below the limit of quantifi-
cation (data not shown).
Determination of arsenic in serum samples by AAS
The average serum concentration- versus time curve is presented in Fig. 2.
No arsenic was detected in samples taken before treatment. Immediately after the in-
jection (t= 15 min) of melarsoprol 527-770 ng/ml of arsenic was found (average 657 ±
90). 124-171 ng/ml of arsenic (average 147 ± 20 ng/ml) was measured 24 h after appli-
cation (Table IV).
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Determination of melarsoprol by HPLC and bioassay
Before the first injection of melarsoprol the activity in the serum determined by biologi-
cal assay was insignificant (8 - 19 ng/ml), and no melarsoprol was detected by HPLC.
The average Cmax concentration of melarsoprol after 15 min determined by HPLC was
found to be 720 ng/ml compared to 4925 ng/ml calculated by bioassay. With HPLC the
determined half life of melarsoprol was calculated to be less than an hour. In samples
taken 3 h after application no melarsoprol was found by HPLC (Table V and VI).
Drug levels in CSF
In CSF samples taken at various time points no arsenic, melarsoprol or melarsen oxide
levels above the limit of quantification could be detected by AAS (50 ng/ml) and HPLC
(16 ng/ml, 50 ng/ml). In contrast, low concentrations were determined by bioassay: 1 h
after application 28 and 32 ng/ml (patient 1 and 2), 6 h after the application 78 and 139
ng/ml (patient 5 and 4) and 24 h after application 34 ng/ml (patient 3) were found. No
arsenic could be detected by AAS at any time point in the CSF samples of the five pa-
tients (see Tables III; IV; V; VI).
Evidence for further metabolites
The molar melarsoprol concentrations determined by bioassay corresponded to the
molar concentrations of arsenic of the samples. However, the HPLC concentrations of
melarsen oxide and melarsoprol were not equal to the sum of the concentrations de-
termined by bioassay. In samples taken 24 h after the injection, no melarsoprol and
melarsen oxide could be determined by HPLC, but activity and arsenic could still be
detected.
In conclusion there is evidence that melarsoprol is metabolised into melarsen oxide,
which rapidly undergoes further transformation into one or more active compounds still
containing the arsenic moiety.
Characterisation of further metabolites
Several derivatives and fragments of melarsoprol were tested in vitro for their trypano-
cidal activity. It could be demonstrated that the activity is associated with the arsenical
part of the compound: The trivalent arsenicals, melarsen oxide, melarsoprol and phen-
ylarsen were highly active (Minimum Inhibitory Concentration MIC = 1 - 6.5 ng/ml). The
pentavalent form melarsen and the inorganic arsenic oxide (MIC = 50 mg/ml and
111 ng/ml) were considerably less active. Melamine and dimercaprol (BAL, British Anti
Lewisite), two non-arsenic chemical constituents of the drug melarsoprol, were inactive
(see Table VII).
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The discrepancy between the short half life of melarsen oxide and the long terminal
half life of activity as determined by bioassay indicates that further active products of
melarsoprol are formed. The in vitro testing of fragments and derivatives of melarsoprol
suggests that an arsenic metabolite is formed.
However, no further metabolites could be detected either by HPLC-UV using 0, 5, 10,
15 and 30 ml acetonitrile up to 100 ml HPLC water in the supernatant of microsomal
incubations or in the supernatant of precipitated samples of melarsoprol treated pa-
tients. Determination of the activity by in vitro assay of the chromatographic fractions of
the supernatant of precipitated human samples did not reveal any activity. The results
are supported by AAS determination of the arsenic concentration in precipitated human
serum and CSF samples with several solvents as described. In all the samples only
traces of arsenic were found in the supernatant, but most of the arsenic was detected
in the protein pellet. Also the precipitation of a pooled liquor sample and analysis of the
pellet for arsenic revealed a high concentration of 400 mg/kg of arsenic bound to pro-
teins (Table VIII). These results indicate a strong binding of the metabolite to serum
and also to CSF proteins. An irreversibly bound drug is defined as one only liberated
from the isolated protein by saponification 22.
To test further whether the drug is irreversibly bound to plasma proteins according to
the definition, the protein pellet was boiled at 80°C for one hour in KOH. Still only 30%
of the total arsenic could be detected in the supernatant. The result was further con-
firmed by ultrafiltration: A 10 fold higher activity in the filter residue was determined
compared to the filtrate using filters exclusion sizes of 5 kD, 10 kD and 20 kD. Only fil-
ters with large pores (100 kD) yielded an equal activity of the residue and the filtrate,
indicating that the metabolite is bound to macromolecules larger than 20 kD.
A confirming in vitro experiment gave further evidence for the irreversible nature of the
binding of melarsen oxide to serum proteins: 900 mg/kg of the arsenic was recovered in
the protein pellet from a melarsen oxide spiked serum sample. In presence of p-
hydroxymercuribenzoate 1300 mg/kg of the arsenic could be detected in the protein
pellet, which rules out an exclusive As-S binding (Table VIII).
In vivo activity studies of melarsen oxide
In vivo acute rodent model infections
100% cure rates were achieved by administering the drug intraperitoneally (2.2 mg/kg) and
intravenously (range 0.1 – 1 mg/kg) (Table VII).
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In vivo relapse rodent model infections
Three mice receiving one dose of 40 mg/kg berenil, a drug which is not capable of
passing the blood brain barrier died on day 13, 52, and 55 after treatment. Of six mice
treated with 5 mg/kg of melarsen oxide for seven subsequent days 5 survived for 180
days; while one died on day 83.
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Discussion
Drug metabolites may contribute or be solely responsible for drug action or adverse
effects 14. Occasionally their pharmacological properties are superior to those of the
parent compound 23. Thus, the metabolic pathway must mandatorily be sufficiently
documented for each new drug. Surprisingly, the pharmacology of the first choice drug
for treatment of 2nd stage sleeping sickness, melarsoprol is still poorly elucidated half a
century after its development. Adverse effects with an essentially unexplained back-
ground hamper the application of the drug 2. Therefore, we have attempted to study
the metabolism of this organoarsenical drug.
The active drug dominating in the body is melarsen oxide and not melarsoprol, which
has a half life of less than 30 minutes in plasma. We could demonstrate that melarsen
oxide is the first metabolite, confirming a recently published hypothesis 13. Melarsen
oxide is rapidly formed in the body and maximum levels (Cmax) are reached after 15
minutes. It then disappears fast from the plasma with an apparent half-life of 3.8 hours.
Previous experiments showed that melarsen oxide is formed from melarsoprol by hy-
drolysis 13. However, the breakdown of melarsoprol measured in vitro after incubation
with serum at room temperature was found to be a slow process with a half-life of 3
days 17. Hence, it cannot be excluded that melarsen oxide may also be formed to
some extent by enzymatic reactions. Since melarsoprol is the BAL derivative of melar-
sen oxide, another possible explanation for the discrepancy might be the known insta-
bility of British Anti Lewisite (dimercaprol, BAL) complexes in vivo 24.
Melarsoprol’s first metabolite, melarsen oxide was synthesized by E. Friedheim in 1939
and in use for several years 25. However, after the discovery of BAL the drug was
abandoned in favor of melarsoprol.
The very short half-life of melarsen oxide is not solely due to a fast elimination. It was
demonstrated that one of the metabolic products formed is bound to plasma proteins of
a size of more than 20 kD. Both proteins which are commonly responsible for drug
binding, albumin (66 kD) and a1-acid-glycoprotein (44 kD), fall into this category. The
drug might also become bound to antibodies, tissue proteins or red blood cells. Due to
the irreversible nature of the binding the protein-drug product cannot longer be deter-
mined by HPLC, but activity remains detectable by bioassay. The present data do not
allow to conclude whether melarsen oxide alone, or also melarsoprol or further unrec-
ognised metabolic products are bound to proteins. The mechanism of the covalent
binding and the reactive groups of the proteins are unknown. NH2 groups of the pro-
teins could serve as reactive nucleophiles for the arsen oxide of melarsen oxide. Hence
the formation of a Schiff base and following spontaneous Amadori rearrangements may
be proposed 3.
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The bound active compound acts as a reservoir that is depleted very slowly. This is in
line with the recently published serum and CSF multiple-dose kinetics. A long half life in
serum (t1/2 = 35 hours) and a very slow elimination from the CSF (t1/2= ca. 120 hours)
were calculated, and a delayed increase of the CSF levels was proposed 11, 12. In
contrast, the drug can be detected in the CSF already after 1 hour by both, the bioas-
say and HPLC.
Melarsoprol is only soluble in propylene glycol, an irritating solvent. Administration is
very painful and thrombophlebitis at the injection side is a common feature. Little atten-
tion has been paid in the past years to improve the way of administering the drug,
though earlier small scale studies indicated even oral activity 26. Melarsen oxide is
more polar, a 36 mg/ml stock solution in propylene glycol could be diluted 1:2 in water
compared to the necessity of a 1:500 dilution of melarsoprol.
The use of melarsen oxide as a trypanocidal compound was abandoned due to its tox-
icity 4. However, other reports state equivalence of toxicity when melarsen oxide and
melarsoprol were compared 27. It could be demonstrated that dimercaprol (BAL) does
not contribute to the trypanocidal activity. In contrast, its contribution to drug toxicity
cannot be excluded. BAL is a toxic compound with a LD50 of 1.48 mmol/kg if applied
intraperitoneally to rats 28. Further on BAL complexes of trypanocidal drugs may even
be more toxic than the arsenical drug itself. For example, the complex of dimercaprol
and oxophenarsine has a substantially higher toxicity compared to oxophenarsine 29.
To confirm the activity we tested melarsen oxide in a relapse infection mouse model.
Mice were treated for 7 days with 5 mg/kg melarsen oxide i.v. The results indicate that
melarsen oxide passes the blood brain barrier in sufficient concentration.
Adverse effects are common in melarsoprol treatment and the underlying reasons may
be manifold. Covalent binding of drugs or drug metabolites have been reported to be
cause of severe adverse effects due to immune reaction of type I to IV, as the altered
macromolecules may turn into an immunogen. The extent of such reactions is influ-
enced by genetic and host factors and the disposition of the conjugate 30. The interac-
tion of penicillines with the immune system is a classical example of such a hapten
formation: The carbonyl moiety of the opened b- lactam ring forms an amide linkage to
the amino groups of proteins. The resulting penicilloyl- protein conjugate is the trigger
for anaphylaxis 31.
The trigger for the encephalopathic syndromes is still unknown. Generally, an involve-
ment of the immune system is proposed today, but the underlying causes are still con-
troversial. Hunter and colleagues suggested that insufficient drug levels leading to
complete elimination of trypanosomes from the bloodstream but not the CSF, may pro-
voke a violent inflammatory response of activated astrocytes after restoration of the
immune competence 8. Other researchers proposed that high initial doses result in
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massive killing of trypanosomes leading to the release of immuno-complexes attracting
subsequently an array of antibodies 32. On the other hand it was suggested that the
immune response was directed against the arsenical or its derivatives bound to para-
site proteins, because the reactions were observed in both stages of disease unrelated
to dose and schedule 7. Considering the diversity of hypothesis, at least a part of the
reactions may be due to a immune reaction against the protein bound metabolite.
It is clear that all organoarsenic compounds are far from optimal. However, there will
not be any satisfactory alternatives available for clinical use in sleeping sickness ther-
apy for a long time to come. In this light the elucidation of the cause of severe adverse
reactions is of great importance and the presented results may build a basis for a more
rational approach. The elimination of the severe adverse effects may not be possible,
but it must be a primary goal to provide appropriate information on adequate responses
to these life threatening situations. In addition, the findings on melarsen oxide indicate
that an appropriate pre-clinical evaluation of this compound versus melarsoprol might
be of interest.
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Figure 1: Serum drug levels determined by bioassay, HPLC and AAS
Table I: Baseline characteristics of patients
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Sex male male female female female
Age (years) 36 20 20 21 33
Weight (kg) 48 52 37 37 38
Height (cm) 170 166 151 155 152
WBC (No/mm3 in CSF) 400 160 88 64 64
Hb (mmol/l/dl) 5.9 7.7 5.5 5.2 6.0
Glucose (mmol/l) 4.0 1.2 3.2 3.5 1.9
Urea (mmol/l) 5.2 <3.5 <3.5 <3.5 4.0
Creatinine (µmol/l) 49.5 49.2 56.6 <45 58.3
Bilirubine (µmol/l) 9.9 8.6 8.7 <8.5 18.8
GPT (U/l) 7.7 5.8 4.5 7.2 22.7
Table II: Pharmacokinetic properties of melarsen oxide as determined in human patients
Pharmacokinetic proper-
ties
Patient 1 Patient 2 Patient 3 Patient 4 (Patient 5) Average SD
Clearance CL [ml/min*kg] 17.6 20.7 22.6 25.4 (5.3) 21.5 3.3
Area under the curve
    AUC [ng/ml*h*kg]
2090 1770 1630 1440 (6820) 1733 274
Volume Vss [l/kg] 4.7 5.5 6.1 7.7 (15.6) 6.0 1.2
Half life t½ [hours] 4.7 3.2 3.5 4.0 (34.7) 3.9 0.7
Table III: Melarsen oxide concentrations in ng/ml determined by HPLC in serum and CSF
Time Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Average SD
Serum
Before application <50 <50 <50 <50 <50 <50 n.a.1
After application:
15 minutes 848 508 715 648 461 636 157
1 hour 426 302 288 225 238 296 80
3 hours 129 256 150 (75)2 178 68
6 hours 77 90 76 (150)2 81 8
8 hours 62 56 49 (140)2 56 7
24 hours <50 <50 <50 <50 <50 <50 n.a.1
CSF
Various timepoints <50 <50 <50 <50 <50 <50 n.a.1
1not applicable; Empty cells represent missing samples
2data not used for calculation of pharmacokinetic parameters due to assaying difficulties
Table IV: Arsenic concentrations in ng/ml determined by AAS in serum and CSF
Time Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Average SD
Serum
Before application <50 <50 <50 <50 <50 <50 n.a.1.
After application:
15 minutes 691 770 676 527 619 657 90
1 hour 351 530 378 381 443 417 72
3 hours 228 282 241 346 271 274 46
6 hours 176 209 261 198 211 36
8 hours 139 163 184 256 167 182 44
24 hours 124 147 165 171 132 147 20
CSF
Various timepoints <50 <50 <50 <50 <50 <50 n.a.1
1not applicable; Empty cells represent missing samples
 Table V: Melarsoprol concentrations in ng/ml determined by bioassay in serum and CSF
Time Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Average SD
Serum
Before application 8 7 19 12 17 12 n.a.1
After application:
15 minutes 4550 4675 6300 4200 4900 4925 809
1 hour 2930 4090 2900 2290 3550 3152 688
3 hours 1478 1920 1900 1241 1860 1789 209
6 hours 1300 1200 1350 1283 76
8 hours 998 1100 1100 1320 1185 1140 120
24 hours 796 1070 747 816 846 855 125
CSF
Various timepoints 28
  (1 hour)
32
 (1 hour)
34
(24 hours)
139
 (6 hours)
78
 (6 hours)
n.a.1 n.a.1
1not applicable; Empty cells represent missing samples
  Table VI: Melarsoprol concentrations in ng/ml determined by HPLC in serum and CSF
Time Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Average SD
Serum
Before application 0 0 0 0 0 0 n.a.1
15 minutes 602 1026 668 601 706 720 176
1 hour 71 103 75 38 72 72 23
3 hours 0 0 0 0 0 0 n.a.
6 hours 0 0 0 0 n.a.
8 hours 0 0 0 0 0 0 n.a.
24 hours 0 0 0 0 0 0 n.a.
CSF
Various timepoints <50 <50 <50 <50 <50 n.a.1 n.a.1
                                                 1not applicable; Empty cells represent missing samples
Table VII: In vitro activity of melarsoprol and related compounds
Compound
tested
Formula MIC1
Melarsoprol 6.5 ng/ml
Melarsen oxide 6.5 ng/ml
Melarsen 50 mg/ml
Phenylarsen 1 ng/ml
Arsenic oxide As2O3 111 ng/ml
Melamine >100 mg/ml
Dimercaprol C3H5OH(SH)2 11 mg/ml
1Minimal Inhibitory Concentration
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Table VIII: Arsenic content of precipitated samples
Solvents used for pre-
cipitation of serum
samples
Total melarsoprol con-
centration (bioassay) in
mg/L
Arsenic concentration (AAS) of
supernatant in mg/L
0.05 M zinc sulphate in
50% water/ acetonitrile
765 8
7 M NaOH 380 54
TCA 531 10
DMSO 380 12
Proteinase K 540 4
Boiling 1 hour with 1M
KOH
1440 60
b-mercaptoethanol 500 2
Table IX: In vivo activity of melarsen oxide in an acute infection model
Dose of melarsen oxide (mg/kg/day) No. mice cured/ No.
mice total
% mice cured
Control
2.2 mg/kg i.p
0/5
5/5
0
100
Control
0.1 mg/kg i.v.
0.5 mg/kg i.v.
1 mg/kg i.v.
0/5
5/5
5/5
5/5
0
100
100
100
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Abstract
Melarsoprol, an organo-arsenical, drug has been the drug of choice for late stage trypano-
somiasis since 50 years. Due to the lack of alternatives any abatement of this medication will
have a dramatic negative impact on the perspectives for the treatment of the infected. A high
number of patients refractory to melarsoprol treatment was recently reported from Northern
Uganda and Northern Angola. A study was carried out in Northern Angola to investigate
whether interpatient pharmacokinetic differences influence the outcome of melarsoprol
treatment. Drug levels were determined by a biological assay in serum and cerebrospinal
fluid of a total of 22 patients. 9 patients could be successfully treated, 8 were refractory and
of 5 the outcome was unclear or no adequate follow up information was available. No differ-
ences in the pharmacokinetic parameters (maximum serum concentration Cmax, half-life t1/2,
total clearance CL and the volume of distribution Vss) could be detected between the groups.
The serum and CSF concentrations for all patients were in the expected range. This result
indicates that other underlying factors are responsible for treatment failures.
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Introduction
The estimated number of people infected with Trypanosoma brucei gambiense (sleeping
sickness) dramatically increased during the last decade. The countries currently most af-
fected are the Democratic Republic of Congo (DRC) and Angola (Smith et al. 1998). Treat-
ment of trypanosomiasis is still mainly based on melarsoprol and any abatement of the value
of this drug will have a dramatic negative impact on the perspectives for the treatment of the
infected. Until today treatment failures were a known feature, but remained at rather low and
constant levels of 1 - 10% (Pepin & Milord 1994; WHO 1986) during the last fifty years. How-
ever, this situation has radically changed after recent reports of much higher rates of treat-
ment refractory patients from Northern Uganda and Northern Angola. The Ugandan National
Sleeping Sickness Control Program (NSSCP) had started a control program in collaboration
with Médecins sans Frontières (MSF) in the Arua District and reported a rate of treatment
failures of 26.9% during an observation period of 24 months (Legros et al. 1999b). The An-
golan National Institute for Combat and Control of Trypanosomiasis, ICCT reported 25% pa-
tients refractory to treatment from a center in Mbanza-Congo, Zaire Province run by Angotrip,
Caritas Angola (Angotrip Caritas Angola, unpublished data). Treatment failures were defined
as trypanosomes detectable in any sample of a patient within one month after treatment, or a
complete lack of clinical response during the course of treatment, followed by rapid deterio-
ration of the patients and death (unpublished data).
Treatment failures may have different causes: Possible reasons are the emergence of para-
sites with divergent biological features permitting either to advance to deeper compartments
or to counteract the activity of drugs, pharmacological differences of certain individuals or
populations leading to insufficient drug levels in critical body compartments, and reinfections.
The approaches and strategies to bring this menacing situation under control are obviously
different for either reason and thus it is of importance to rapidly elucidate which event under-
lies this novel situation.
Generally, the effects of a drug in terms of activity or toxicity may show considerable interpa-
tient variation (Rowland & Tozer 1989), either resulting from different concentrations at the
site of action (kinetic differences) or from different responses to a given drug concentration
(dynamic differences). Differences in drug metabolism with a pharmacogenetic background
are common (Rowland & Tozer 1989), and may be increased by external influences, like
food or concomitant drug application.
The aim of the presented study was to investigate the influence of pharmacokinetic differ-
ences on the outcome of melarsoprol treatment of late stage trypanosomiasis. We have also
conducted ancillary experiments on isolated trypanosomes from the patients enrolled in the
study to further elucidate the background of the treatment failures.
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Patients and methods
Study design
The study was carried out at the trypanosomiasis treatment center of M’banza Congo, Zaire
Province, Angola, which is under the responsibility of the ICCT and maintained by Angotrip,
Caritas Angola.
The inclusion criteria of the study were a confirmed second stage T. b. gambiense infection,
which was either confirmed serological or parasitological (trypanosomes detected in the
cerebrospinal fluid (CSF) and/or >5 white blood cells (WBC) /mm3 detected in the CSF by
microscopical investigation) and an age ³14 years. Patients, or their responsible guardians in
severe cases, were informed about the trial and asked for consent.
Melarsoprol treatment was performed according to the schedule of the ICCT (see Figure 1).
All patients were pre-treated with chloroquine (1500 mg base) and mebendazole
(100mg/bid/3d). Prednisolone was given at 1 mg/kg bw, 0.5 mg/kg, 0.25 mg/kg during the
first, second, and third series of standard treatment, respectively. One tablet of a folic acid-
iron combination was given daily.
For pharmacokinetic analysis the patients were categorized into three groups: (i) “treatment
successful” i.e. no parasites detectable by microscopy in blood, lymph and/or CSF samples
in any sample collected at treatment control performed within 48 hours after the last applica-
tion of melarsoprol, and/or the first follow up examination attempted thirty days thereafter; (ii)
“treatment failure” i.e. patient died during treatment with no clinical improvement, parasite
positive in any sample examined at treatment control or upon the first follow up examination;
(iii) “outcome unknown” i.e. patients without retrievable follow up information or unclear re-
sults (e.g. trypanosome positive with a very high WBC count, death for unconfirmed reasons
within the first follow up period).
No regular follow up of the patients for 24 months according to the guidelines of the ICCT
was possible due to the deteriorating political situation in the study area, which escalated in
the evacuation and partial destruction of the center nine months after the study period and
made access to the region impossible.
The study protocol was approved by the Ethics Committee of the University Hospital in
Basel, Switzerland, and the Ethics Committee of the Ministry of Health in Luanda, Angola.
Patient population
Overall, 22 patients (13 female and 9 male) under treatment for late stage sleeping sickness
were enrolled and subjected to sampling. 11 patients had been treated in the center before
(19 – 45 days, median 43 days, after termination of last treatment), and 11 were cases re-
porting for the first time. Both groups were treated identically (see Figure 1). The age, body
mass index (weight/height2) and WBC count were determined at hospital admission.
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Parasitological assessment
Patients reporting to the center were initially screened using the CATT-test (Magnus et al.
1978; WHO 1998). Positive cases or suspect patients with negative CATT results underwent
lymph node puncture. The aspirate was microscopically checked for trypanosomes. If the re-
sult was negative, capillary blood was examined. Lumbar puncture was carried out for all
positive cases detected by any method. The disease stage was determined by microscopical
examination of the CSF for trypanosomes, and by counting of WBC.
Sampling and determination of drug levels
One full blood sample for the isolation of trypanosomes and KIVI kit was taken before treat-
ment.
A total of 6 serum samples for drug level determination were collected from each patient:
Before, 0.5, 6, 24, 48 and 72 hours after the last melarsoprol application of one of the series
of treatment.
Samples were taken during the first treatment course from 3 patients, during the second
treatment course from 8 patients, and during the third treatment course from 10 patients.
One CSF sample for parasitological assessment and drug level determination was taken by
spinal tap 24 or 48 hours after the last injection of melarsoprol, coinciding with the respective
serum sample. The CSF collected upon diagnosis was used as blank control sample if avail-
able.
Serum samples were prepared from full blood and left for coagulation at ambient tempera-
ture for 30 minutes, centrifuged with a hand centrifuge (Hettich, Tuttlingen, Germany) for 10
minutes, frozen in a dry shipping liquid nitrogen container (Harsco CP 65, Taylor-Wharton,
Camp Hill, PA, USA), transported to Luanda, transferred into an other dry shipping liquid ni-
trogen container (Harsco CP300, Camp Hill, PA, USA) and transferred to the Swiss Tropical
Institute in Basel, Switzerland for analysis. CSF treatment samples were frozen in liquid ni-
trogen immediately after collection and shipped accordingly.
The drug levels in the samples collected were determined using a bioassay (Onyango et al.
2000).
Pharmacokinetic analysis
For categorization of the patients see study design. The data of one patient (patient 1, group
“treatment failure”) were not used for analysis because of severe difficulties with preparation
of his serum samples (only marginal serum amounts retrievable).
Samples of the three treatment courses were treated equally, as the levels and decay melar-
soprol concentrations of each therapy course are comparable (Burri et al. 1993).
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For calculation of the pharmacokinetic parameters a two compartment model was fitted to
the individual concentration vs. time data of the patients with equation (1) using the Topfit
software (Heinzel, 1993).
Cp = A * e
- t + B * e- t    (1)
The differences among the three treatment groups were tested by ANOVA.
Genetic analysis
Trypanosome karyotyping of two strains isolated from refractory patients was done following
the method of Van der Ploeg (Van der Ploeg et al. 1984), and described in detail by Degen
(Degen et al. 1995). The method used was appropriate to separate chromosomes between
225 and 2200 kb. T.b. gambiense strains from Northwest Uganda and the Democratic Re-
public of Congo were used as a reference.
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Results
Of the 22 patients enrolled 9 (41%) were considered successfully treated, remaining parasi-
tologically negative at the first follow up examination planned after 30 and performed within
22 - 90 days (median 42 days) after the last application of melarsoprol. 5/9 (56%) of the suc-
cessfully treated patients had a history of one previous unsuccessful melarsoprol treatment
(median 43 days before the second treatment).
8 patients (36%) were considered treatment failures according to the definitions (see study
design). 2 patients died during the ongoing treatment without any clinical improvement. 2 pa-
tients were trypanosome positive in blood and CSF at control examination within 48 hours
after the last application of melarsoprol. 4 patients were found positive upon the first follow
up examination performed 22 – 38 days (median 34 days). 4/8 (50%) patients of this group
were previously treated once with melarsoprol without success. The data of one patient (pa-
tient 1, group “treatment failure”) were not used for analysis because of difficulties with serum
sample preparation (see methods).
5 patients had an unknown or unclear treatment outcome. Of 2 of those no information was
retrievable, two patients died within 2 months after treatment without any further parasitologi-
cal examination, and one was trypanosome negative but had a WBC count of 367 mm3 44
days after treatment. 2/5 (40%) patients were previously treated once with melarsoprol with-
out success (overview see Tables 3, 4).
The continuous variables at baseline among the three groups were within a similar range
(weight: F2,18= 0.34 (p= 0.71); body mass index:  F2,13= 2.38 (p= 0.13); WBC: F2,14= 0.93 (p=
0.42) (Table 1).
Results of the pharmacokinetic analysis
Maximum drug serum levels (determined 0.5 hours after the last application of melarsoprol
ranged from 3635 ng/ml to 10838 ng/ml with an overall mean of 6209 ng/ml. After 24 hours
drug concentrations between 874 ng/ml and 2190 (mean 1300 ng/ml) were determined. Half
an hour after drug administration serum levels were considerably higher in the “treatment
failure” and “unknown outcome” groups. At all subsequent timepoint no differences were
found between any of the groups (see Figure 2).
The average drug concentration in the CSF 24 hours after melarsoprol application were
38.9 ng/ml in the “successful treatment” group (n=3) and 70.5 ng/ml for treatment refractory
patients (n=3). A sample from one patient of the successfully treated group and the treatment
failure group were collected after 48 hours (19.3 ng/ml collected after the second treatment
series; 60.3 ng/ml after the third series) (Figure 3).
No differences for any of the calculated pharmacokinetic parameters was found between the
three groups by ANOVA analysis: Clearance (CL): F2,18= 0.61 (p= 0.55); AUC: F2,18= 0.54
Treatment failures in Northern Angola                                                                                                84
(p= 0.59), volume of distribution (VSS): F2,18= 1.2 (p= 0.32); half life (t1/2): F2,18= 0.13;
(p= 0.88). The detailed pharmacokinetic parameters are given in Table 2.
Results of the genetic analysis
The analysis of the intermediate-large sized chromosomes revealed for both isolates an
identical intermediate pattern, which was similar to the reference strains (both isolates ex-
pressed one additional band). Also the results of the large size chromosome analysis
showed a similarity of the isolates to the gambiense reference strains, only the chromosomes
larger than 2.2 Mb were distinguishable from the reference strains. These results confirm the
T.b. gambiense nature of the isolated trypanosomes.
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Discussion
Recent activities in Northern Uganda and Angola revealed high frequencies of treatment fail-
ures with melarsoprol of 26.9% (Legros et al. 1999a; Legros et al. 1999b) and 25%, respec-
tively (personal communication Dr. Mendoza Casillas, Caritas Angola). Interestingly, a single
earlier report indicates a rate of up to 40% of treatment failures in the Lower-Zaire (Demo-
cratic Republic of Congo) (Ruppol & Burke 1977), including patients who remain parasite
positive in the blood during the course of treatment. This report was reiterated by Pepin
(Pepin & Milord 1994), who indicated the close proximity of the Lower-Zaire and the Northern
Angola region. After 1975 there was a considerable migration in both directions due to the
political situation in the area.
None of the enrolled patients were previously treated with melarsoprol more than once. The
strategy of Caritas was to treat all refractory patients with DFMO. However, only very limited
quantities were available at this point of time, which explains the attempt to retreat one of the
studied patients with melarsoprol, after a first unsuccessful attempt. T.b. gambiense infected
patients who are retreated with melarsoprol after failing to respond to treatment are less
likely to be cured compared to those treated for the first time (Legros et al. 1999b; Pepin &
Milord 1994). The therapeutic success in the investigated patient population is summarized
in table 3, but our data set is too small to perform statistical significance tests for this finding.
Prior to study initiation the following sources of treatment failures were excluded: Inferior Ar-
sobal® (melarsoprol) quality and inadequate performance of hospital staff. The quality of
melarsoprol (Lot 705) was confirmed by HPLC analysis and the conduct of biological drug
susceptibility assays. The handling and administration of the drugs were checked upon an
auditing visit and found to be appropriate.
We could not find any evidence for differences between the pharmacokinetics of melarsoprol
in patients successfully treated compared to those refractory to treatment. The average drug
levels analyzed in all three groups are similar to those previously published:
The melarsoprol concentrations in plasma immediately after the last melarsoprol application
of a treatment series (6273 ng/ml; SD 2108 ng/ml; n=19) were slightly higher but in the same
range compared to those recently reported by Bronner (Bronner et al. 1998) (4045 ng/ml; SD
964 ng/ml; n=7). In samples taken 24 hours after the last melarsoprol application of a treat-
ment series the drug concentrations were similar at 1342 ng/ml (SD 437 ng/ml; n=20) com-
pared to 1686 ng/ml (SD 881 ng/ml; n=8) (Bronner et al. 1998). Also the CSF drug levels of
64 ng/ml (SD 38 ng/ml; n=9) 24 hours after the last drug application of a series were similar
to those previously reported (42 ng/ml; SD 17 ng/ml; n=8) (Bronner et al. 1998). The calcu-
lated average half life (t1/2) of 42 hours, and the average total clearance (CL) of 1 ml/min*kg
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are comparable to the respective values from preceding studies (t1/2 35 hours, CL
1 ml/min*kg) obtained from late stage patients treated in the Ivory Coast (Burri et al. 1993).
The mechanisms leading to the increased rate of failures of melarsoprol treatment are pres-
ently under investigation.
Reinfections may account for a varying proportion of treatment failures, especially in areas
with high transmission rates. However, the sharp increase of treatment failures and the ob-
servation of patients with trypanosomes detectable in body fluids within less than thirty days
after treatment termination is not likely to be caused by this event. Due to the defined control
period of only thirty days, the influence of reinfections on the outcome can almost be ex-
cluded.
Among several possible mechanisms of drug resistance in trypanosomes (Maser & Kamin-
sky 1997), a decrease in drug uptake is the most frequently reported. Cellular uptake of
diamidines and melaminophenyl arsenicals is thought to occur via an adenosine transport
system designated P2 (Carter & Fairlamb 1993). A gene, TbAT1, encoding a P2-type adeno-
sine transporter has recently been cloned from T. b. brucei (Maser et al. 1999). Expression of
TbAT1 in yeast enabled adenosine uptake and conferred susceptibility to melaminophenyl
arsenicals. A mutant, apparently non-functional variant of TbAT1 has been found in drug-
resistant laboratory and field strains of T. brucei spp. (Maser et al. 1999). The isolation from
the enrolled patients of trypanosomes for drug susceptibility assessment was attempted by
KIVI kit (Truc 1996) and by cryopreservation. However, of 15 KIVI samples and 22 collected
by cryopreservation only two procyclic isolates could be cultivated from KIVI kits. Of the
cryopreserved isolates none could be grown in rats. Transformation to bloodstream forms
was unsuccessfully attempted by in vitro metacyclogenesis (M. Fasler, personal communica-
tion). The passage of the trypanosomes to tsetse flies was not attempted for the potential
danger to laboratory staff. Procylic forms cannot be used for testing of drug susceptibility
therefore no results are available. Due to persistent political unrest the M’banza Congo re-
gion remains completely inaccessible and additional collection of samples for further analysis
was obstructed.
Alternative mechanisms of reduced drug susceptibility are discussed. A reduction in lipoic
acid content has been observed in melarsen-resistant trypanosomes (Fairlamb et al. 1992),
and selection for resistance to mycophenolic acid resulted in amplification of the inosine
monophosphate dehydrogenase gene in T. b. gambiense (Wilson et al. 1994). The pathways
involved in environmental sensing in trypanosomatids were recently reviewed (Parsons &
Ruben 2000). It may be hypothesized that differences in the signal pathways may produce
distinct affinities of such trypanosomes, permitting to advance to deeper compartments
where only marginal drug levels can be reached.
No satisfactory clinical alternative to melarsoprol will be available in the near future. The oc-
currence of high treatment failure rates stresses the urgent need for research to develop new
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drugs for human African trypanosomiasis. We provide evidence that pharmacokinetic differ-
ences among the patients can be excluded. This stresses the need for further studies of the
causes of melarsoprol treatment failures.
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Table 1: Comparison of continuous variables at hospital admission
Group
Treatment successful Treatment failure Outcome unknown
N Mean c.v. n Mean c.v. n mean c.v.
Age (years) 9 39.0 46.8 7 34.3 32.4 5 27.6 45.4
Weight (kg) 9 51.1 10.1 7 49.1 10.3 5 48.8 16.1
Height (cm) 6 162.7 3.9 7 165.3 5.7 3 164.7 2.9
BMI (kg/m2) 6 19.2 6.6 7 18.1 14.2 3 16.1 8.9
WBC 9 1751 3 781 5 4281
Total patients 9 7 5
1Median
c.v. = coefficient of variation
Comparison of pharmacokinetic parameters in serum
Group
Treatment successful Treatment failure Outcome unknown
Mean Min Max c.v. n Mean Min Max c.v. n mean Min
5303 3900 7235 23.21 7 7006 3635 10786 32.50 5 6544 3935
1267 986 1885 28.1 7 1344 874 2087 36.3 5 1296 1008
1.03 0.68 1.57 31.8 7 1.05 0.595 1.83 39.4 5 0.85 0.61
3.48 1.71 4.8 32.8 7 3.14 1.98 4.61 32.8 5 2.56 1.12
21’211 12’700 29’200 28.9 7 21’328 10’900 33’600 33.8 5 24’720 17’900
42.9 27.9 70.3 31.1 7 42.8 28.1 74.8 39.4 5 39.3 28.6
Patients with successful treatment (9), 1 ser 1, 4 ser 2, 4 ser 3
Patients with treatment failure (7) 1 ser 1, 1 ser 2, 5 ser 3;
Patients with unclear outcome (5) 1 ser 1), 3 ser 2, 1 ser 3
Data of one patient failing treatment were excluded due to sampling problems
coefficient of variation
Table 3: Categorization of patient based on treatment outcome and previous treatment
Actual treatment Previous treatment
Yes No Total
Successful 5 4 9
Failure
    (within 30 days)
41 4 81
Not known 2 3 5
Total 11 11 221
1The data of one additional patient were not used for evaluation due to problems at sample processing
and consequently largely deviating results
Treatment outcome (previous and actual)
Treatment
outcome
Interval since last
treatment [days]1
Follow up period
[days]2
Information available
(failure)3 43 35 Trypanosomes in blood, CSF negative
Retreatment with DFMO
failure n.a.4 died during treatment
(parasitology unclear)
No clinical response to treatment
failure 35 15 Trypanosomes in blood, CSF positive
Retreatment with DFMO
success n.a. 60 Blood negative, CSF positive
success n.a. 48 Blood negative, CSF positive
failure n.a. 15 Trypanosomes in blood, CSF positive
success 45 90 Fair condition, no details
unknown 44 n.d. none
success 42 55 Blood negative, CSF negative
failure 45 died during treatment No response; treatment switched to
DFMO, no response, died under treat-
ment
failure n.a. 38 Trypanosomes in lymph
failure n.a. 22 Remained critically ill under treatment
Blood negative, CSF positive
died 3 days after examination
failure 40 33 Trypanosomes in lymph
Blood negative, CSF negative
unknown n.a. 44 Blood negative, CSF negative
367 WBC in CSF
unknown n.a. Died for unknown reason max. 2 months after
treatment (exact time-point unknown)
success n.a. 30 Blood negative, CSF negative
unknown 19 n.d. none
success 44 30 Blood negative, CSF negative
unknown n.a. 28 Died for unknown reasons
(CSF negative at discharge)
success 49 49 (360)6 Blood negative, CSF negative
success 40 n.d. Oral information, patient in good condition
success n.a. 70 Blood negative, CSF negative
Last melarsoprol application of previous treatment to hospital admission
 Last melarsoprol application to first follow up examination
Patient not included in pharmacokinetic evaluation because of sampling problems
First melarsoprol treatment
At examination 24 hours after treatment termination
Reported for follow up to Trypanosomiasis Reference Center, Viana Luanda
Figure 1: Schedule for late stage sleeping sickness treatment with melarsoprol (Na-
tional sleeping sickness program Angola)
Day of drug application
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
M1 M2 M3 M3 M1 M2 M3 M3 M1 M2 M3 M3
   M1= melarsoprol 1.2 mg/kg bw; M2= 2.4 mg/kg bw; M3= 3.6 mg/kg bw
: Serum drug levels determined by bioassay
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Figure 3: Drug concentrations in the CSF
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Summary
160 fluoroquinolones and derivatives were tested for antitrypanosomal activity in a
drug sensitivity assay followed by fluorometric evaluation. The most active quinolone
compounds had IC50 values in the range from 100 ng/ml to 900 ng/ml, while several
derivatives were not active at a concentration of 100 mg/ml. A structure activity rela-
tionship study was carried out: structural modification of the quinolones at position
R1, R2, R3, and R8 did not influence trypanocidal activity. An exchange of the fluor
at position 6 may contribute to an increase in activity but does not entirely control the
activity. Pyrrolidine substituents at position R7 were in general more active than other
substituents at this position. Tetracyclic quinolone derivatives were amongst the most
active compounds with IC50 values in the range of 0.3-8.8 mg/ml.
The in vitro cytotoxicity on HT-29 cells was determined for active compounds with
IC50 values below 1 mg/ml. In addition six drugs with an IC50 below 1 mg/ml and a se-
lectivity index of more than 10 were chosen for in vivo experiments. Dose escalation
experiments with a maximum dose of 100 mg/kg/bid were performed in a mouse
model without central nervous system involvement. For unknown reasons the in vitro
effect of the drugs could not be confirmed in vivo, but the class of compound remains
of interest for their mode of action, the low toxicity, pharmacological properties and
the availability of a large number of synthesized compounds.
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Introduction
Human African trypanosomiasis is a fatal disease caused by the protozoan parasites
Trypanosoma brucei gambiense in Central and West Africa, and T.b. rhodesiense in
East Africa. About 55 million people in 36 countries are at risk of acquiring the dis-
ease (WHO, 1998) and the number of people infected is dramatically increasing
(Smith et al., 1998). There is no prospect of an antitrypanosomal vaccine, due to the
ability of the parasite to readily change its surface antigens which results in an inade-
quate immunity response of the host (Wang, 1995). Therefore the clinical manage-
ment of sleeping sickness relies entirely on chemotherapy. However, only a few
drugs are available which all may cause severe adverse effects, and are generally
expensive (WHO, 1998). Chemotherapy has made very little progress over many
decades: the main drugs for the treatment of the first stage of disease are suramin
and pentamidine were introduced in 1922 and 1941. The organo-arsenic drug melar-
soprol (Arsobal®) (Friedheim, 1949) is still the drug of choice for treatment of the late
stage, when the parasites have invaded the central nervous system. Only one drug,
eflornithine (a-difluoromethylornithine) was brought to the market in the last decade.
However, the compound, originally developed as an antitumor drug, is only active
against T.b. gambiense and almost unaffordably expensive (WHO, 1998). Recent re-
ports on treatment failures and drug resistant trypanosomes are source of new con-
cerns (Pepin et al., 1994, Van Nieuwenhove, 1998). In consequence new antitry-
panosomal compounds are urgently needed.
Fluoroquinolones are a class of synthetic antibacterials, which offer a broad spectrum
of activity, combined with excellent pharmacological and pharmacokinetic properties
like high plasma levels, high clearance, oral and parenteral applicability, chemical
stability and rare side effects. The penetration of the CNS has been demonstrated ki-
netically and clinically (Scheld, 1989). Early compounds of this class of drugs were
active against Gram-negative bacteria, whereas newer ones have a broad spectrum
affecting Gram-negative and -positive bacteria, including anaerobic pathogens
(Wolfson and Hooper, 1989). Fluoroquinolones are specific inhibitors of topoisomer-
ases, which are ubiquitous enzymes essential for cell survival. Topoisomerases me-
diate the mechanistic interactions like supercoiling, relaxation, knotting or catenating
of DNA double helices (Maxwell and Gellert, 1986). Kinetoplastid protozoa have a
unique and complex type of mitochondrial DNA, composed of thousands of topologi-
cally interlocked circular DNA molecules, creating a high demand for topoisomerase
activity (Englund et al., 1982). The required enzyme activity in combination with the
rapid proliferation of trypanosomes makes the inhibition of topoisomerases an inter-
esting potential drug target. In vitro activity against trypanosomes, Plasmodium fal-
ciparum and Leishmania donovani of quinolones has already been reported (Croft
and Hogg, 1988, Raether et al., 1989, Nenortas et al., 1999).
We have determined the in vitro activity against human trypanosomes of 160 se-
lected quinolones with chemical variations in order to evaluate structure-activity rela-
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tionships and antiparasitic selectivity. Six compounds were furthermore evaluated in
vivo.
Material and Methods
Drugs
Quinolones were kindly supplied by DuPont pharmaceuticals (DuPont 5a-5w, 15a-e,
9a-c, 16b, 16c, 17, 19, 22, 24-29); Kanebo Ltd. Pharmaceutical Division (Kanebo 8a-
c, 8f-h); Johannes Gutenberg Universität Mainz, Fachbereich Chemie (UM 35, UM
36); University of Ljubljana, Department of Chemistry and Chemical Technology
(Metal quinolones UL 1-5); University of Barcelona, Laboratory of Microbiology, De-
partment of Sanitary Microbiology and Parasitology, Division of Health Sciences,
Faculty of Pharmacy (E-4535, E-4534, E-4528, E-4527); Daiichi Pharmaceutical Co.
Ltd. (DU 6859a); Hokuriku Seiyaku Co. Ltd. (HSR 903); Dong Wha Pharm Ind. Co.
Ltd. (DW 116, DW 271); Pharmazeutisches Institut der Universität Bonn (H 1-H 10);
Universita di Messina Istituto di Microbiologica Dipartimento di Scienze Farmaceu-
tiche Universita Degli Studi Di Firenze (VG 6/1, MF 5137, MF 5168, MF 5101, MF
5142, MF 5124, WF 1); Laboratorios Dr. Esteve (E-4696, E-4629, E-4628, E-4591,
E-4811, E-4555, E-4695, E-4630, E-4715, E-5091, E-4619, E-5112, E-4625, E-4626,
E-4724, E-4685, E-4936, E-4868, E-4935, E-5100, E-4548, E-4487, E-4497, E-4654,
E-4549, E-4550, E-4572, E-4627); Biotech Research Institute (LB 20304); Bayer AG
(Gatifloxacin); Grünenthal GmbH (Moxifloxacin); Glaxo Wellcome, Verona (G 64070,
G 67012, G 71258, G 59030, G 72800, G 71286); Universidad Nacional de Cordoba,
Facultad de ciencias quimicas (Sulfanilyl Fluoroquinolones); Universidad Central de
Venezuela (UV 1-17); Dipartimento di Scienze Farmaceutiche, Università di Trieste
(V 1, V 2). Stock solutions of 10 mg/ml in 0.1 M NaOH or DMSO were prepared and
stored at – 20°C.
In vitro testing of activity
The trypanosome clone STIB 900 a cloned derivative of T.b. rhodesiense STIB 704,
isolated 1982 in Tanzania, was used for in vitro growth inhibition studies. Blood-
stream forms were cultured in Minimum Essential Medium (MEM) with Earle’s salts
(powder, GIBCO/BRL No. 072-01100 P) supplemented with 25 mM HEPES, 1 g/l
additional glucose, 2.2 g/l NaHCO3 and 10 ml/l MEM nonessential amino acids
(100x). The medium was further supplemented according to Baltz (Baltz et al., 1985).
The Alamar Blue sensitivity assay was carried out as previously described (Räz et
al., 1997): bloodstream forms of T.b. rhodesiense were inoculated into 96-well micro-
titer plates (Costar, USA). The trypanosomes were incubated with the serial drug di-
lutions for 70 hours at 37°C in 5% CO2. Then 10 ml Alamar Blue were added and af-
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ter two hours of incubation the fluorescence was determined at an excitation wave-
length of 530 nm and an emission wavelength of 590 nm.
HT-29 cells (human adenocarcinoma cells) were cultivated in MEM supplemented
with 10% heat inactivated foetal bovine serum and maintained at the same conditions
as the trypanosomes. The highest drug concentration used for all substances was
100 µg/ml. The IC50 (concentration inhibiting the growth by 50%) values were calcu-
lated by linear interpolation (Huber and Koella, 1993). The cytotoxicity assay was
performed according to the method of Pagé (Pagé et al., 1993) with minor modifica-
tions. 5000 HT-29 cells/100 ml culture medium were incubated in the presence of the
drugs in various concentrations. The assays were analysed as previously described.
In vivo testing of activity
Selection of compounds
Substances with an IC50 value for trypanosomes below 1 µg/ml and a selectivity in-
dex (defined as the ratio of the minimum inhibitory concentration of mammalian cells
to that of trypanosomes) (Kaminsky et al., 1996) of more than ten fold were selected
for in vivo testing.
Acute infection model
Animals: female CD1 mice (20-25 g) were purchased from Charles River, Germany.
The animals were infected intraperitoneally with 2*105 trypanosomes of STIB 704.
Experimental treatment with the respective compounds was started 24 h after infec-
tion. The initial drug doses were calculated such that the plasma concentration would
correspond to the IC50 levels as determined in the in vitro assays for the respective
drugs. For calculation a volume of distribution of 3 l/kg was assumed. During the ex-
periment the doses were increased to a maximum of 100 mg/kg. The drugs were
administered intraperitoneally twice a day for two consequent days (see Table 2).
Untreated control groups (n= 2-4) were included. Animals were checked for parasites
twice weekly in tail vein blood. Animals surviving for more than 30 days were consid-
ered as cured.
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Results
In vitro studies
160 quinolones derivatives were tested for activity against a clone of T.b. rhodesi-
ense using serial dilutions with a maximum concentration of 100 µg/ml following the
method described by Räz (Räz et al., 1997). The IC50 values determined in vitro are
given in Table 1 (see appendix). The metal quinolone UL 5 was the most potent
compound with IC50 values of 100 ng/ml. DW 271, Kanebo 8g, Kanebo 8h, and the
two sulfanyl fluoroquinolones N(CH3)2SNx and OCH3SNx were reasonably active,
with IC50 concentrations in the range of 300 ng/ml up to 900 ng/ml. Some of the
DuPont compounds, developed as antitumor drugs, were highly active but also
showed high cytotoxicity on HT-29 cells.
In vivo studies
No parasitological cure of mice could be achieved with any of the compounds tested
in dose escalation experiments up to 100 mg/kg i.p. The detailed results are shown in
Table 2. No signs of toxicity were observed during the experiments.
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Discussion
In the past years the quinolones compounds progressed to the most important drugs
in antibacterial therapy due to their broad spectrum against gram-positive and gram-
negative bacteria and their minor adverse effects and toxicity. They possess many
pharmacological advantages which have made them to excellent therapy for urinary,
respiratory, gastrointestinal, skin or sexually transmitted diseases (Neu, 1990). Due
to an increasing resistance problem new compounds are continuously developed,
and an array of structural derivatives of the quinolone nucleus have been synthe-
sized. Fluoroquinolones are known to inhibit topoisomerases, but GABA, amino acid,
and adenosine receptor interactions have also been reported (Takayama et al.,
1995). For those reasons we have launched a project to investigate the curative po-
tential of this class of drugs against sleeping sickness.
In vitro structure activity relationship
We tested 160 fluoroquinolones and their derivatives against cultured bloodstream
forms of T.b. rhodesiense. Each structural modification of the quinolone core (see
Figure 1) leads to characteristic in vitro activity and toxicity. By comparison of the try-
panocidal in vitro activities structure relationships of the compounds tested were
elaborated and are discussed.
                                                                          Figure 1
Position R1
Substitution at N1 is not prerequisite for trypanocidal activity (e.g. various DuPont en-
tities).
Position R2
Derivatization at this position is not directly associated to antitrypanosomal effect.
Chemically different moieties like hydrogen (e.g. DW 271), phenyl (DuPont 5s) and
styrylphenyl (e.g. DuPont 16b, 19, 24) exist in active drugs. However, modification
with a melaminylgroup of the positions 1 and 2 yields generally moderately active
compounds. The same groups are present in most drugs currently in use active
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against human and animal trypanosomiasis (melarsoprol, pentamidine, berenil and
samorin).
Position R5
This position is known to control bacterial potency and Gram positive activity, the op-
timal groups being NH2 and OH followed by CH3 (Domagala, 1994). However, we
found no evidence for an impact on trypanosomal activity. Compounds with a Cl- or
NH- or methyl-substitution were generally not trypanocidal. The activity of DW 271
can rather be explained by the substitution at position 7.
Position R6
Most marketed quinolones are F substituted at position 6 (fluoroquinolones). Re-
placement at this position of the F with Cl, Br or MeO yielded activity in the µM range
in some instances (e.g. DuPont 5v, 9b, 9c or 24), but the effect was not consistent.
These drugs were developed as anticancer drugs. Their mode of action is known to
inhibit the tubuline function of cells leading to a high cytotoxicity against mammalian
cells (Hamel et al., 1996). The DuPont derivatives were therefore not followed in vivo.
Drugs with modification at R6 only, yielded an increase of activity in the following or-
der: anthra> methyl> AcO> F. In conclusion position 6 may contribute to, but does
not exclusively control for activity.
Position R7
Pyrrolidine derivatives offer the highest therapeutic efficacy against Gram- positive
bacteria, while the piperazines derivatives have better efficacy against Gram- nega-
tive strains (Domagala, 1994). Screening for trypanocidal activity yields higher activ-
ity for a pyrrolidine substituent (e.g. DW 271, LB 20304, HSR 903, DU 6859a, Moxi-
floxacin) over piperazin (e.g. Ciprofloxacin), azedinyl (e.g. E-4535) or NH substitution
(e.g. DuPont 25). Further substitution of the pyrrolidine ring does not seem to lower
the activity (e.g. DW 271). However, the substitute at positions 1 (large group) or 8
(electronegative) may completely abolish the activity of pyrrolidine derivatives. From
the compounds screened it is not possible to deduct which of the positions has a
larger influence (DU 6859a and HSR 903). The sulfaninyl-fluoroquinolones, see Ta-
ble 1, were active though possessing a piperazine ring.
Phenyl- piperazinyl- butoxyl substitution at R7 yields inconsistent results, but the ac-
tivity was generally low.
Position R8
In bacteria the optimal groups at this position for high in vivo and in vitro activity are
N, CF, and CCl (Domagala, 1994). For trypanocidal activity substitution at R8 is not
essential. However, it may modify the potency in conjunction with substitution at
other positions (see R7).
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Other structures
The thiazolopyrazines tested are quinolones with a unique tetracyclic structure and a
modified morpholino group at position 7. Besides the quinolones modified at position
7 with a piperazinyl group, this set of compounds was most consistent in terms of in
vitro activity. Particularly those drugs carrying a single side chain at the morpholino
rest (Kanebo 8f – 8h) were active in vitro in the nanomolar range.
In vivo activity
The registered drugs ciprofloxacin and fleroxacin have a volume of distribution of
0.4 l/kg and 2.5 l/kg (Chukwuani et al., 1998). For calculation of the initial doses of
the compounds to be tested in vivo an average volume of distribution of 3 l/kg was
assumed. The initial doses were defined such that the plasma concentrations
achieved  would correspond to the IC50 levels determined in the in vitro assays for the
respective drug. Doses were applied twice a day since the drugs are known to have
a short half-life, DW-271 having a half-life of 2.9 hours (Won Yong Lee, Dong Wha
Pharm Ind. Co. Ltd., personal communication). The experiment was continued by
dose escalation to a maximum of 100 mg/ml (UL 5 max. 10mg/kg due to limited solu-
bility). In contrast to the promising in vitro results none of the compounds showed any
curative effect at any dosage level and the blood of treated mice was not cleared
from trypanosomes. No signs of toxicity were observed during the experiments.
The reason for the in vivo ineffectiveness cannot be explained by the results at hand,
as no drug level determination in the plasma of the treated mice was performed. It
may be hypothesized that the compounds have a very short half-life due to rapid
elimination or metabolism, or have a very large volume of distribution all potentially
leading to insufficient drug levels.
In conclusion several of the investigated quinolones revealed a remarkable in vitro
activity. This, in combination with the complete lack of any toxic signs at all dosage
levels tested in vivo, makes this class of compounds very attractive for further search
for trypanocidal compounds despite the failure to confirm the promising in vitro activ-
ity in this set of experiments. Based on the results obtained special attention should
be paid to the R7-substituted- and the tetracylic derivatives.
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Table 2: In vivo activity of selected derivatives
Compound Dose Number cured
vs. number
total
Survival time
Kanebo 8g 2.4 mg/kg 0/4 10/12 days
Kanebo 8g 9.6 mg/kg 0/2 10 days
Kanebo 8g 100 mg/kg 0/2
Kanebo 8h 0.9 mg/kg 0/4 10/12 days
Kanebo 8h 3.6 mg/kg 0/2 10/11 days
Kanebo 8h 100 mg/kg 0/2 10/11 days
DW 271 2.1 mg/kg 0/4 10/11 days
DW 271 8.4 mg/kg 0/2 9 days
DW 271 100 mg/kg 0/2
Metal quinolone 5 0.3 mg/kg 0/4 10 days
Metal quinolone 5 1.2 mg/kg 0/2 9/10 days
Metal quinolone 5 10 mg/kg 0/2 10/11 days
N(CH3)2SNx 2.7 mg/kg 0/4 12 days
N(CH3)2SNx 10.8 mg/kg 0/2 9 days
N(CH3)2SNx 100 mg/kg 0/2
OCH3SNx 2.7 mg/kg 0/4 13 days
OCH3SNx 10.8 mg/kg 0/2 9 days
OCH3SNx 100 mg/kg 0/2
Control (included
for each dose
elevation)
- 0/4 9 days
Discussion                                                                                                                              113
Consequences of the biotransformation of melarsoprol, a
discussion
The aim of this PhD thesis was to investigate the metabolism of melarsoprol, the
main drug in use for the treatment of human African trypanosomiasis. The apparent
discrepancy between the results of two assays (bioassay and HPLC) in determining
melarsoprol concentrations in human body fluids encouraged to carry out a thorough
study of melarsoprol’s metabolism. Metabolic studies are, next to the strategies of
screening and research on targets, a promising method for the discovery of a new
drug for sleeping sickness: Metabolites often have more desirable properties than the
parent drug and knowledge of the metabolic pathway and the enzymes involves
helps to avoid severe adverse effects.
Generally, the process of drug metabolism can be regarded as a mechanism of de-
toxification: In order to facilitate the excretion of foreign, lipid soluble, nonpolar com-
pounds (e.g. many drugs) from the body, they are converted into more hydrophilic
compounds. Metabolic reactions of xenobiotics are classified into two types: Phase I
reactions involve intramolecular rearrangements as oxidative, reductive or hydrolytic
reactions. The metabolites may undergo further metabolism in phase II, enzyme
catalysed conjugations. Less commonly the metabolite is formed spontaneously be-
cause of inherent chemical instability.
Under some circumstances, however, metabolism can lead to the formation of pro-
ducts, which possess a higher activity as the parent drug and augment its effect. On
the other hand some metabolites have a different pharmacologic profile and may
even be the cause of adverse effects or toxicity (Rowland and Tozer, 1989).
We have found that melarsoprol is hydrolyzed within minutes to the active drug
melarsen oxide due to instability of the dimercaprol (BAL) complex. Melarsen oxide is
the synthetic precursor of melarsoprol before the complexation with BAL, but is no
longer commercially available. Melarsen oxide has a short half-life of about 3.8
hours; the reactive oxide is capable of binding covalently to macromolecules. It was
demonstrated that melarsen oxide and potential metabolites of melarsoprol are irre-
versibly bound to serum proteins, resulting in a stable drug complex.
These interesting, but also problematic results of the study of melarsoprol’s metabo-
lism demonstrated difficulties researchers might face in the process of drug devel-
opment: The developed drugs or metabolites lack activity, are toxic or as in our case
reveal unexpected properties. The result that melarsoprol has inherently problematic
pharmacologic properties encouraged to pursue in parallel a second strategy well
established in our laboratory: To screen chemicals of a certain class in order to dis-
cover a lead compound acting on a biological target of trypanosomes.
The discovery of the rapid hydrolysis of the BAL complex raises the two main ques-
tions I would like to discuss: First, whether it is actually beneficial to complex melar-
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sen oxide with BAL and second whether the numerous adverse effects that occur in
the treatment with melarsoprol are due to the irreversible bound metabolite.
Melarsen oxide versus mela rsoprol
The development of melarsoprol
Melarsen oxide was synthesized by Friedheim in 1939 and subsequently used as an
antitrypanosomal drug in a series of trials mainly in the 1940’s and 1950’s (see Table
1).
In view of these trials it can be summarized that in sufficient doses and applied intra-
venously, melarsen oxide seemes to be able to cure late stage trypanosomiasis.
However, the reports on the concentration of the effective intravenous dose of melar-
sen oxide ranged from 1.5 mg/kg (Friedheim, 1948) to 3 mg/kg as the minimum ef-
fective dose (Jonchere, Gomer et al., 1953). The reports on oral effectiveness are
questionable and most publications do not provide any information on relapse cases
and follow up studies.
In 1946, first results on a new detoxifier of arsenic, British Antilewisite (BAL or dimer-
caprol) were published. Applied to animal skin the substance revealed protection
against the vesicant action of the chemical warfare agent lewisite (Danielli, Danielli et
al., 1946). However, animal trials with rats showed that BAL possessed a low LD50 of
50 mg/kg if applied intramuscular (Danielli, Danielli et al., 1946) and 110 mg/kg if ap-
plied subcuteanously (Webb, 1946). It was supposed that the toxicity of BAL was due
to its affinity to a large number of enzymes (Webb, 1946). The high toxicity and the
necessity to administer the antidote soon after arsenic contamination restricted the
systemic use of BAL (Danielli, Danielli et al., 1946). Today BAL is hardly used as an
arsenic antidote and most clinicians believe that the drug is useless (Mückter, Liebl et
al., 1997, Apted, 1980). Recently an increase of mortality after the administration of
BAL for treatment of melarsoprol induced encephalopathic syndromes has been re-
ported (Pepin, Milord et al., 1995).
Nevertheless, Friedheim started to combine arsenicals with BAL, having in mind an
increase of tolerance of the drug melarsen administered in combination with a “high
protein diet in form of Swiss cheese” (Friedheim, 1959); patients in the Volta region
received during treatment “large chunks of cheese” and Friedheim speculated that
the decisive factor of the reduced incidences of adverse effects might be the sulfur
content of the cheese. The trivalent arsenic was capped with the sulfur groups of the
dimercaptan. Among the complexed drugs were atoxyl, stovarsol, oxophenarsine, or-
sanine, tryparsamide and melarsen oxide (Friedheim, 1959). However, investigations
on the complexed compounds revealed an increased toxicity, the LD50 of oxophenar-
sine was found to be 15 mg/kg compared to 4 mg/kg of the Marph-BAL complex
when applied intramuscularly to rats (Peters and Stocken, 1946). In contrast, com-
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plexes of oxophenarsine with the better tolerated and less toxic antidote dimercaprol
glycoside did not show an enhancement of toxicity. It was discussed that an increase
of toxicity of the complexed compounds could be due to the instability of the complex,
the dissociation of dimercaprol (Peters and Stocken, 1946).
However, Friedheim did not abandon dimercaprol and based on promising results
from trials with melarsen oxide (melarsen oxide was reported to be the first drug to
cure late stage T. b. gambiense infections without toxic incidences in very high num-
bers) he focused on the melarsen oxide-BAL complex melarsoprol (Mel B)
(Friedheim, 1959). Mel B received considerable attention terminating the use of
melarsen oxide though the advantages of melarsoprol compared to melarsen oxide
were questionable. Adverse effects were common during treatment with melarsoprol
despite the arsenic theoretically being detoxified by the capping. Several clinicians
assessed the advantages and disadvantages of melarsoprol over melarsen oxide: A
direct comparison of both drugs demonstrated a similar toxicity of both compounds
(Jonchere, Gomer et al., 1953):
Table 2: A comparison of Melarsoprol and Melarsen oxide (Jonchere, Gomer et al., 1953):
Melarsen oxide Melarsoprol
Arsenic content 22.3 % 18.8 %
LD50 (mouse) expressed in
means of arsenic content of
drug
7.3 mg/kg 6.5 mg/kg
LD 50 (mouse) expressed as
total drug
32 mg/kg 30 mg/kg
Total dose used without
complications
10.5 mg/kg
(7 injections of 1.5 mg/kg)
10.8 mg/kg
(3 injections of 3.6 mg)
Findings and conclusions
Today this controversy on the treatment of sleeping sickness has still not been re-
solved, but it has even been forgotten. Melarsoprol is still the drug of choice for
treatment of the late stage of the disease but its future production is questionable.
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Our single dose kinetic study indicated that the dissociation of melarsoprol, into
melarsen oxide and BAL, in the body is rapid. One hour after application of the first of
ten doses of 2.2 mg/kg only 38-103 ng/ml of melarsoprol and after three hours no
drug could be detected by HPLC in serum of patients. Cmax of melarsen oxide is
reached already 5-15 minutes after the intravenous drug application (see Investiga-
tions of the trypanocidal drug melarsoprol).
We demonstrated that dimercaprol itself possessed no activity on trypanosomes. It is
a rather toxic compound with a LD50 of 1.48 mmol/kg (mouse, i.p.) (Mückter, Liebl et
al., 1997). Therefore, contributions of BAL to melarsoprol’s toxicity cannot be ex-
cluded.
Melarsoprol is only soluble in propylene glycol due to the lipophilicity of dimercaprol.
Because of its viscosity it is difficult to administer the drug. The application is painful
and a thrombophlebities at the injection site is frequently developed. In contrast
melarsen oxide is more hydrophilic and would thus be better water soluble and easier
to administer.
Interestingly BAL has been shown to redistribute arsenic to the brain and tissues
(Mückter, Liebl et al., 1997). Therefore this molecule may enhance the passage of
melarsoprol through the blood brain barrier.
With the exception of a series of clinical trials conducted in the mid of the century,
which revealed contradictory results, no data are available on the ability of melarsen
oxide to pass lipophilic membranes as the blood brain barrier. Therefore we investi-
gated in a late stage infection mouse model whether melarsen oxide is capable of
passing the blood brain barrier in a sufficient amount for cure: The mice were fol-
lowed up for 180 days and 5/6 mice could be cured receiving 7 doses of 5 mg/kg in-
travenous (see: Investigations on the trypanocidal drug melarsoprol).
Future possibilities
In view of our findings melarsen oxide appears to be a valid alternative to melarso-
prol for clinical use. Therefore, in depth preclinical studies on several doses and
routes of application in an appropriate animal model might be indicated to compare
melarsen oxide with melarsoprol. The optimal dosage for melarsen oxide for cure of
human African trypanosomiasis, with lowest rate of relapses and adverse effects
should eventually be determined. If successful, the logical continuation would be a
clinical trial in the setting of an “expanded access” protocol:
Under current US law, for example, all new drugs need proof that they are effective
and safe and have to undergo extensive clinical testing before they are approved for
marketing. This is a time-consuming and expensive process. In the case of metabo-
lites this process might be facilitated and more rapid as baseline data already exist.
The parent drug melarsoprol, however, is a drug, which is known to cause adverse
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effects. Surprisingly to date hardly any appropriate information on its safety profile or
chemical and kinetic properties exist. Therefore no data can be employed for its me-
tabolite melarsen oxide. However, the Food and Drug Administration launched initia-
tives for urgently needed drugs for life-threatening diseases, that have no acceptable
treatment so far: These innovative programs allow the compounds to be used in “ex-
panded access” protocols, which are unrestricted studies in order to learn more
about the drug while providing treatment. One prominent example is zidovudine:
4,000 AIDS patients were treated with zidovudine before it was approved and the
drug was finally brought to the market only 107 days later (Flieger, 1993).
Melarsen oxide in the treatment of Human African trypanosomiasis
Dose Treatment schedule No. cured/ No. total Observations Reference
150 mg oral Not known Not known No adverse effect (Van Hoof, 1946)
25 mg
intravenous
Not known Not known No adverse effect (Van Hoof, 1946)
0.1 mg/kg
intravenous
7 days 5/5 first stage
1/3 late stage
- (Weinmann and Franz,
1945)
3 mg/kg
oral
5-8 days 4/4 first stage 11/12 late stage
(followed up 4 month)
Arsenic recovered in
brain, liver and kidneys
after melox administra-
tion
(Weinmann and Franz,
1945)
1.5 mg/kg intrave-
nous
7 days, 2 series with 1
month interval
No results on follow up - (Nodenot, 1947)
3 mg/kg oral 8 days, 2 series ?/13 (results published soon
after end of treatment)
- (Nodenot, 1947)
? Oral Two series of seven days
with 10 days break
1/6 late stage - (Rouzic, 1949)
0.0015 mm/kg in-
travenous
Two series of seven days
with one month break
5/7 late stage - (Rouzic, 1949)
1 cg oral Two times 1cg 9/9 first stage
0/5 late stage
Doses of 3 cg tolerated.
Single dose of melox ef-
fective
(Trinquier and Pellisier,
1948)
1.5 mg/kg intrave-
nous
2 series of 7 injections 54/54 late stage (immediate
effect)
5/5 follow up 10 month
- (Friedheim, 1948)
1.5 mg/kg intrave-
nous
Two series of seven days
with one month break
10/10 late stage Adverse effects observed (Ceccaldi, Arnoult et al.,
1949)
0.1 mg/kg intrave-
nous
7 days ?/74 late stage (relapses after
2 years reported)
Adverse effects observed (Duggan and Hutchinson,
1951)
2.5 mg/kg
intravenous
Three injections during 3
days
10/12 late stage Dose insufficient (Jonchere, Gomer et al.,
1953)
2.5 mg/kg
intravenous
Two series of three injec-
tions with three weeks
break
4/5 late stage Dose insufficient (Jonchere, Gomer et al.,
1953)
3 mg/kg intrave-
nous
Three injections during 3
days
9/9 late stage
only 3 month follow up
Adverse effects observed (Jonchere, Gomer et al.,
1953)
3 mg/kg intrave-
nous
Two series of three injec-
tions with three weeks
break
5/5 late stage
only 3 month follow up
Adverse effects observed (Jonchere, Gomer et al.,
1953)
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Bound metabolites and associated adverse effects
General remarks
Adverse effects appear to be an inevitable complication of chemotherapy. They ac-
count for a large amount of fatal reactions and are responsible for a significant number
of patient’s deaths: Adverse reactions are reported to have an overall incidence of 10-
20%, to cause 2-3% of consulations in general practice and up to 3% of admission to
acute care hospital wards (Laurence and Bennett, 1993)
Various classifications of adverse drug reactions have been proposed (Park, Pirmo-
hamed et al., 1992; Hess and Rieder, 1997). They are often divided into four types: un-
predictable (idiosyncratic) drug reactions, predictable reactions, reactions associated
with long term drug therapy and delayed effects.
(1) Intolerance, allergy (they account for 10-20% of all adverse drug reactions and may
even have a fatal outcome) or pseudoallergy are typical reactions of unpredictable ad-
verse effects. So far, mechanisms of unpredictable adverse effects are not well under-
stood, they are unpredictable from the knowledge of the basic pharmacology of the
drug, unrelated to the intended pharmacologic effect of the medication, do not show
any simple dose-response relationship and occur in only a small percentage of the
population (hence the term idiosyncratic). Knowledge of the pharmacology of the drug
does not assist to the identification of individual patients at risk (Hess and Rieder,
1997). To alleviate the adverse reaction a drug discontinuation rather than dose reduc-
tion is required (Park, Pirmohamed et al., 1992). Aplastic anaemia occuring after chlor-
amphenicol administration is a typical example for unpredictable adverse effects
(Pirmohamed, Kitteringham et al., 1994).
(2) In contrast, predictable adverse drug reactions are dose- dependent host inde-
pendent and can be anticipated from the known pharmacology of the drug. Predictable
adverse effects are common and include overdosing of drugs, drug-drug interactions or
drug-disease interactions. Careful planning of treatment can reduce the incidence of
predictable, dose dependent adverse effects (Hess and Rieder, 1997). Examples of
this type of reaction include hypoglycaemia with oral hypoglycaemics and hypotension
with anti- hypertensives (Park, Pirmohamed et al., 1992).
(3) Examples of adverse effects associated with long term therapy, as benzodiazepine
dependence or analgesic nephropathy are well described and can be anticipated (Park,
Pirmohamed et al., 1992).
(4) Delayed effects such as carcinogenicity and teratogenicity are classified as type 4
reactions (Hess and Rieder, 1997). Today such toxicities should be precluded by the
extensive programme of preclinical mutagenicity and carcinogenicity studies that a new
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chemical entity must undergo before a product license is granted (Park, Pirmohamed et
al., 1992).
Metabolites are known to cause unpredictable adverse effects: Reactive molecules
formed spontanously or by phase I and phase II enzymes, bind to essential cellular
macromolecules through covalent bond formation and interfere with normal physiologi-
cal functions or even generate an immune response against the altered macromole-
cule.
Melarsen oxide, melarsoprol’s metabolite is a typical example of a reactive metabolite.
Immune reactions:
                                              Drug
                                                                             Cellular protein      Interference
                    Bioactivation                                                                   with cell function
    Genetics or              Chemically reactive            Covalent Binding
    Environment                   Metabolite
                   Bioinactivation                                     Serum protein        Hapten
                                        Detoxification
                                                                                                              Antigen
                                                                                                 Cellular          Humoral
                                                                                                Response       Response
                                                                                                     Immune Reaction
In order to trigger an immune reaction the molecule must have a minimum molecular
weight of 1,000 Da (Pohl, Satoh et al., 1988). Thus, a drug once covalently bound can
initiate a misdirected immune reaction. This immune reaction is directed against the
drug (haptenic epitopes), the carrier protein (autoantigenic determinants), or against
the whole complex. The altered macromolecule may provoke a humoral or cellular re-
sponse, or a combination of both. Cellular activation includes the production of excita-
tory cytokines, clonal expansion and the recruitment of activated macrophages. A hu-
moral response is elicited by antibody production through the interaction of B cells with
T cells activated by antigen-presenting cells (Hess and Rieder, 1997). Important drugs
for the production of toxic metabolites are butazones, chloramphenicol, anticonvul-
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sants, sulphonamides, phenothiazines or antithyroid drugs (Pirmohamed, Kitteringham
et al., 1994).
Coomb’s classification of the pathological processes involved in immunologic hyper-
sensitivity reactions can be applied for drugs. Frequently a combination of all types is
observed:
(1) Binding of IgE antibodies and antigen to mast cells stimulates the release of chemi-
cal mediators such as histamine.
(2) Antibody response directed against own cells lead to immune activation and to cell
destruction.
(3) Formation of immune complexes of antibody and antigen deposited in tissue may
induce local inflammatory response.
(4) A delayed hypersensitivity mediated by T-lymphocyte responses to antigen.
The clinical manifestation of hypersensitivity reactions is complex and any organ might
be affected. Adverse effects like fever, hepatitis, and nephritis or tissue toxicity are of-
ten observed. Urticaria or dermatitis are frequent symptoms which are produced by the
release of mediators, such as histamine or leukotrienes. The skin is immunologically
functional and metabolically active, containing both phase I and phase II enzymes
(Pirmohamed, Kitteringham et al., 1994). Even reactions in the central nervous system
have been reported. Hypersensitivity reactions to antidepressants, anesthetic agents,
sulfonamides or penicillin in this compartment are well documented, but detailed
mechanism remain unknown. All of these drugs contain a reactive molecule like an
amine group, which is able to form covalent linkage, resulting in a hapten (Hess and
Rieder, 1997).
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An involvement of the immune system during adverse reactions of melarsoprol?
In treatment with the organo-arsenical drug melarsoprol unpredictable adverse effects
are common: A drug-induced encephalopathy is a frequent complication. The reaction
is clinically characterized by a convulsive status associated with high intracranial pres-
sure, psychotic reactions and progressive coma, vomiting, diarrhoea and fever (WHO,
1998). Also hypersensitivity reactions, agranulocytosis, renal and hepatic dysfunctions
have been noted. Skin reactions as maculopapular eruptions, exfoliative dermatitis or
bullous eruptions are inadequately documented, they may be severe but occur infre-
quently (Pepin and Milord, 1994).
The reason for the different individual susceptibility to adverse effects in the treatment
with melarsoprol is not yet known. Our results indicate that a misdirected immune reac-
tion initiated by the covalently bound derivative might trigger the adverse events.
An involvement of the immune system in adverse reactions was already discussed in
the last years, but no final conclusion could be drawn: Hunter and colleagues sug-
gested that parasite persisting in the CSF due to subcurative regimen may provoke a
violent inflammatory response by activated astrocytes (Hunter, Jennings et al., 1992).
Another theory assumed that the massive killing of trypanosomes at treatment start
releases antigens attracting an array of antibodies (Pepin and Milord, 1991). A drug
related immune response by the arsenical or its bound derivatives to parasite proteins
was also already discussed (Haller, Adams et al., 1986).
The involvement of the immune system in the pathogenesis of adverse effects during
melarsoprol treatment is supported by earlier findings:
Independence of dose, dependence of time and host
Typically, immunologic hypersensitivities are reported to be host-dependent but dose-
independent. The reactions usually occur after repeated exposures independent from
treatment schedules and after repeated doses of the drug.
Many authors described the time point of incidences in the treatment with melarsoprol:
Major adverse effects were found to happen at the end of the first series of injections,
during the interval between first or second, or during the second series (Pepin and Mi-
lord, 1991), but also 1 to 3 days after the third injection (Buyst, 1975), or generally after
completion of a three days course (Robertson, 1963). It was reported that incidences
could be avoided with the administration of only a single series of three doses of
melarsoprol (Richet, Lotte et al., 1959) or melarsen oxide (Jonchere, Gomer et al.,
1953). Furthermore, adverse effects were increased if a single application of drug was
divided into several doses at consecutive days (Jonchere, Gomer et al., 1953).
The independence from melarsoprol dosage of the occurrence of adverse effects, in-
cluding the severe encephalopathy was demonstrated in the past using more than 20
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treatment regimens with varying concentration of drug administered: Recently, the effi-
cacy and safety of a new abriged treatment schedule was assessed in an open, ran-
domised equivalence trial in Northern Angola. The new treatment schedule comprised
ten daily injections of 2.2 mg/kg melarsoprol compared to the national Angolan sched-
ule of 3 series of four daily injections of increasing doses from 1.2 to 3.6 mg/kg body
weight: No difference was found in the rate of encephalopathy and the timepoint of the
onset of the reactions between the new and the standard treatment regimen (Chr.
Burri, personal communication). The identical temporal distribution of reaction under
both treatment schedules discounts the hypothesis that non-curative treatment is the
general cause of reaction. A currently published clinical study on the potential efficacy
of melarsoprol in patients with refractory or resistant leukemia implies that not the
parasite is involved in the mechanism of adverse effects, but favour a delayed immune
response or direct toxic drug effect: 3/8 leukemia patients treated with melarsoprol,
using the standard schedule experienced generalised seizures during the second week
of therapy (Soignet, Tong et al., 1999)
Interindividual susceptibilities
It is of interest to know why some patients are more susceptible to adverse effects in
melarsoprol treatment.
Not only exogenous co-factors but also an abnormal pharmacodynamic response, ab-
normality in drug metabolism or idiosyncratic reactions could provide an explanation:
Hypersensitivity reactions have a complex genetic basis, involving numerous proc-
esses that are independently regulated. Individual variation of metabolic processes
might be one trigger since the drug or the drug conjugate are often metabolised before
they are able to activate the immune system. In this regard, some drug-carrier conju-
gates may be more immunogenic than others. In addition, the immune system, con-
sisting of a network of multicellular components, is regulated interindividually resulting
in a different expression of antibodies and other modulators of the immune system.
Halothane hepatitis, one example, can be regarded as a model for immune-mediated
hepatoxicity. Although all patients exposed to the drug are able to generate the anti-
gen, susceptibility to hepatitis is dependent on the immune response of the individual
(Pirmohamed, Kitteringham et al., 1994). Penicillins are another important group of
drugs known for interindividual variation: Studies indicated that the drug induced IgE
antibody response to the penicillolyl antigen is under genetic control (Park, Pirmo-
hamed et al., 1992).
The suggestion that an immunological process might be the trigger for adverse effects
is supported by observations made during melarsoprol treatment of patients suffering
from concomitant diseases: It was reported that the frequency of adverse effects is ag-
gravated by concurrent viral infections such as influenza (Richet, Lotte et al., 1959) and
measles (Buyst, 1975) or parasitic infections such as malaria and onchocerciasis
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(Apted, 1980). In addition, vaccinations for e.g. smallpox were not recommended
(Buyst, 1975).
In general, seasonal and local variations have been noticed in the occurrence of ad-
verse effects. An increase of melarsoprol reaction between June and October (Ancelle,
Barret et al., 1994) and a difference of mortality within regions was reported
(Adriaenssens, 1960; Robertson, 1963; Buyst, 1975).
Reduction of adverse effects by immuno suppressive drugs
Pepin and colleagues clearly demonstrated a significant reduction of encephalopathy
during concomitant prednisolone therapy. A univariate and multivariate analysis of
more than 1,000 patients treated with melarsoprol showed that the fatality rate during
melarsoprol treatment was reduced from 14.2% (patients without prednisolone) to 5.2%
(patients with concomitant prednisolone therapy). The protective effect of prednisolone
was very important: only 3.5 % of the patients developed an encephalopathy. Among
patients who did not experience drug induced encephalopathy, prednisolone had no
effect on mortality (Pepin, Milord et al., 1995). Glucocorticoids like prednisolone effect
the IL-1 synthesis by macrophages and IL-2 production by T- cells, that are necessary
for the proliferation of activated T-cells (Rang and Dale, 1991). Two earlier trials that
evaluated the use of prednisolone to reduce incidences of encephalopathy demon-
strated no effect of the drug. However, the power of the first study was so low that even
a huge effect of prednisolone would not have been detected (Foulkes, 1975), whereas
the data sets of the second study included different treatment regimens applied during
25 years (Arroz, 1987).
A lowered mortality rate during melarsoprol treatment is reported not only from adju-
vant corticosteroid therapy, but also in a few cases from the administration of the two
drugs chloroquine and azathioprine (Buyst, 1975). Azathioprine is known to repress cell
and antibody mediated reactions by inhibition of the polyclonal proliferation in the in-
duction phase of the immune response. Chloroquine hinders phagocytic activity and
the release of mediators during the inflammatory process (Rang and Dale, 1991). In
contrast, the prescription of thiabendazole to treat strongyloidiasis during the melarso-
prol cure was found to increase the risk of encephalopathic syndroms (Ancelle, Barret
et al., 1994). Thiabendazol is a drug, which is known to be given with caution to pa-
tients with a history of drug hypersensitivity,
The results of these studies and our own working hypothesis that an hapten induced
immunological reaction might be responsible for the serious adverse effects, indicates
that prednisolone or similar steroids should be administered during treatment to all pa-
tients. Until the detailed immunologic pathway of adverse events will be elucidated fur-
ther investigations on the effectiveness of different immunosuppressive drugs should
be carried out.
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Continuation of treatment
Symptoms due to an immune reaction usually subside after discontinuation of the
treatment. If the patient is rechallenged with the drug the same unfavorable condition is
observed (with a much more rapid onset). However, if the reactions are not exclusively
immune-mediated, adverse events do not occur immediately after rechallenge with the
drug (Pirmohamed, Kitteringham et al., 1994) or may proceed clinically silent (de Weck,
1991).
Sleeping sickness patients are often retreated with melarsoprol after a short treatment
break without obvious symptoms. Buyst recommended “when the patient survives his
adverse reactions the Mel B course should be continued, but the next injection has to
be postponed for 1-3 days” (Buyst, 1981). In addition, Ginoux and colleagues observed
that each time a patient has survived an encephalopathy the melarsoprol treatment
could be continued without further incident (Ginoux, Bissadidi et al., 1984). This practi-
cal experience is contradictory to the hypothesis of an immune involvement. However,
it is not known whether the patients received steroids during the treatment break,
whether the second immune response proceeds without clinical symptoms, wether the
patients are desensibilised, or whether the toxicity reactions are not exclusively im-
mune mediated (so that the remaining treatment period might be too short to induce
further adverse reactions).
Conclusion
If specific antibodies or T cells can be detected a drug reaction is classified as a hyper-
sensitive drug reaction. The individual susceptibility cannot be predicted so far for most
drugs, which are known to cause unpredictable adverse effects. Lately, in the treatment
with anticonvulsants the lymphocyte cytotoxicity assay, in treatment with penicillins
prospective skin testing has been suggested to predict adverse reactions (Park, Pirmo-
hamed et al., 1992). However, not all predisposed individuals will be identified, espe-
cially if other mechanisms than imunologic factors are involved, and the tests are com-
plex and expensive. An alternative strategy might be to take advantage of the knowl-
edge of the functional group causing the toxicity. Oxide groups (as found in melarsen
oxide) are known to be responsible for a covalent binding of drugs to proteins (Park,
Pirmohamed et al., 1992). This identification may allow the design of new compounds
that retain therapeutic efficacy but do not cause toxicity. Toxic reactions are difficult to
identify. In in vitro systems a general toxicity is revealed rather than complex mecha-
nisms occuring in vivo, and even preclinical safety evaluation in experimental animals
does not identify drugs which cause idiosyncratic reactions in humans. Nevertheless, it
has to be investigated whether the arsenic oxide is essential for trypanocidal activity or
whether it could be replaced.
Examples of this approach to prevent drug toxicity already exist: The nitro group of
chloramphenicol has been replaced by the methylsulphonyl moiety to form thiampheni-
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col, which possesses the same antibacterial spectrum but does not cause aplastic
anaemia (Pirmohamed, Kitteringham et al., 1994). In today’s drug design the presence
of sulphydryl groups or aromatic amino groups is generally avoided because of its toxic
metabolites. Since more than 12,000 arsenicals were synthesized in the beginning of
the century in vitro tests on their activity could be conducted. Pharmacologic properties
like the long half-life of bound drugs have to be kept in mind. Compounds lacking the
reactive group might have a short half-life and thus a low efficacy. In this respect, the ir-
reversible binding of the active compound could act as a reservoir in the body. Interac-
tions of the drug-protein complexes with hepatocytes lead to drug dissociation (Meijer
and van der Sluijs, 1989): Since these endocytic processes in the liver are saturable,
the free drug is available for the target for a period of time. In addition, the mode of ac-
tion of melarsoprol is still not known. Following our results, it could be possible that the
whole drug-protein complex of melarsoprol is active. One example is the active albu-
mine complex of the trypanocidal drug suramin, which enters trypanosomes by endo-
cytosis (Wang, 1995).
A combination of factors acting collectively in individuals may lead to the serious ad-
verse effects in the treatment with melarsoprol and a direct arsenic toxicity can not be
excluded. Since most arsenic derivatives are highly toxic and thus solutions far from
optimal new compounds for the treatment of African sleeping sickness have to be dis-
covered: For our structure activity relationship study compounds of the bacteriocidal
class of quinolones, which mainly act via the inhibition of topoisomerases, were cho-
sen. Topoisomerases mediate topological changes in the DNA, which are essential for
cell survival. Trypanosomes possess a condensed, topologically interlocked circular
type of mitochondrial DNA. The high demand for topoisomerase activity in combination
with the rapid proliferation of trypanosomes makes the inhibition of topoisomerases an
interesting drug target.
Evaluation of a risk benefit ratio for a drug associated with unpredictable adverse ef-
fects is complex. It is even difficult to decide in first world countries whether to withdraw
a drug and protect a certain subgroup of the population and deny therefore the majority
of population access to important therapy. Since we do not have any alternatives in the
treatment of late stage trypanosomiasis we are not confronted with this discussion.
However, it was important to study and elucidate the metabolic pathway of melarsoprol
and its consequences in order to build a basis for future investigations. The presented
results demonstrate that research efforts for new compounds for sleeping sickness
treatment are urgently required.
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Appendix Table I
Structures of tested quinolone derivatives
Registered compounds
Compound Structure Formula IC50 IC50 (TOX)
Ciprofloxacin C17H18FN3O3 Not active n.d.
Norfloxacin C16H18FN3O3 Not active n.d.
Gatifloxacin C19H22FN3O3 16 n.d.
Moxifloxacin C21H25FN4O4 12 n.d.
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Experimental compounds
1. 2-Styrylquinazolin-4 (3H)-ones
Compound X R Formula IC50 IC50 (TOX)
DuPont 5a 6-Cl Ph C16H11ClN2O Not active n.d.
DuPont 5b 5-Cl Ph C16H11ClN2O Not active n.d.
DuPont 5c 7-Cl Ph C16H11ClN2O 2.6 n.d.
DuPont 5d 8-Cl Ph C16H11ClN2O Not active n.d.
DuPont 5e 6-Br Ph C16H11BrN2O Not active n.d.
DuPont 5f 6-I Ph C16H11IN2O Not active n.d.
DuPont 5g 6-F Ph C16H11FN2O 6.2 n.d.
DuPont 5h 6-Cl Me C11H9ClN2O Not active n.d.
DuPont 5i 6-NH2 Ph C16H13N3O Not active n.d.
DuPont 5j H Ph C16H12N2O Not active n.d.
DuPont 5k 6-Me Ph C17H14N2O 1.5 n.d.
DuPont 5l 6-F, 7-Cl Ph C16H10ClFN2O Not active n.d.
DuPont 5m 6,7-(MeO)2 Ph C18H16N2O3 Not active n.d.
DuPont 5n 5-Me Ph C17H14N2O Not active n.d.
DuPont 5o 6-MeO Ph C17H14N2O2 Not active n.d.
DuPont 5p 6-HO Ph C16H12N2O2 Not active n.d.
DuPont 5q 6-F,7-piperidinyl Ph C21H20FN3O Not active n.d.
DuPont 5r 6-EtO Ph C18H16N2O2 Not active n.d.
DuPont 5s 6-F,7-N-Me-
piperazinyl
Ph C21H21FN4O 0.2 1.2
N
N
R
O
X
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DuPont 5t 7-MeO Ph C17H14N2O2 3.3 n.d.
DuPont 5u 6-AcO Ph C18H14N2O3 4.6 n.d.
DuPont 5v 6-anthra Ph C23H17N3O3 0.7 0.4
DuPont 5w H Me C11H10N2O 1.5 n.d.
2. 2-Substituted Quinazolin-4 (3H)-ones
Compound R Formula IC50 IC50 (TOX)
DuPont 15a Me C9H7ClN2O 22 n.d.
DuPont 15b Phenylethynyl C16H9ClN2O Not active n.d.
DuPont 15c Ph(CH2)2 C16H13ClN2O Not active n.d.
DuPont 15d PhCH2 C15H11ClN2O Not active n.d.
DuPont 15e C15H10ClN3O Not active n.d.
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3. Michael Adducts of 2- Styrylquinazolinones
Compound X R Formula IC50 IC50 (TOX)
DuPont 9a Cl N-Me-
piperazinyl
C21H23ClN4O 1.7 n.d.
DuPont 9b Cl N-morpholino C20H20ClN3O2 0.9 0.6
DuPont 9c MeO N-piperidyl C22H25N3O2 0.7 0.4
Compound X A / B Formula IC50 IC50 (TOX)
DuPont 16b Cl CONNH C16H12ClN3O 0.5 1.4
DuPont 17 Cl CSNH C16H11ClN2S Not active n.d.
DuPont 19 Cl RNCN C25H31ClN4 0.6 1.8
DuPont 22 H SO2NH C15H12N2O2S Not active n.d.
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4. Other ring systems
Compound Structure Formula IC50 IC50 (TOX)
DuPont 16c C16H11ClN2O Not active n.d.
DuPont 24 C17H13ClN2O 0.7 1.7
DuPont 25 C14H9N3O4 Not active n.d.
DuPont 26 C14H10N4O3 Not active n.d.
DuPont 27 C19H13N3O 4.6 n.d.
DuPont 28 C14H10N2OS 4.0 n.d.
DuPont 29 C14H14N2O 2.3 n.d.
DU 6859a C19H19F2N3O3 17.3 n.d.
DW 116 C20H18F2N4O3 Not active n.d.
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DW 271 C21H23F2N5O4 0.7 300
HSR 903 C20H23FN4O3*
CH4O3
1.75 n.d.
LB 20304 C18H20FN5O4*
H2O
1.4 n.d.
UM 36 C13H7NF4O3 Not active n.d.
UM 35 Methylester of Compound 36 C14H9NF4O3 16.4 n.d.
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4. Other ring systems (continued)
Compound R6 R7 R8 Formula IC50 IC50 (TOX)
VG 6/1 NO2 CCH3 C23H21N3O5 6.1 n.d.
MF 5137 NH2 CCH3 C23H23N3O3 7.8 n.d.
MF 5168 NO2 CH C18H19N4O5 Not active n.d.
MF 5101 NH2 CH C18H21N4O3 11.6 n.d.
MF 5142 NH2 CH3 C20H24N3O3 16.5 n.d.
Compound R5 R6 R7 R8 Formula IC50 IC50 (TOX)
MF 5124 C4H9 NH2 CH C19H25N4O3 Not active n.d.
WF1 C6H5F NH2 CH C21H21FN4O3 Not active n.d.
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4. Other ring systems (continued)
Compound Structure Formula IC50 IC50 (TOX)
V 1 C16H13N4O 2.3 n.d.
V 2 C16H11ClN5O3 2.7 n.d.
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5. Thiazolopyrazine incorporated tetracyclic quinolones
Compound X Formula IC50(Tryp) IC50 (TOX)
Kanebo 8a C18H16FN3O4S 8.8 n.d.
Kanebo 8b C19H18FN3O4S 1.6 n.d.
Kanebo 8c C20H20FN3O4S 14.6 n.d.
Kanebo 8f C19H17F2N3O4S 1.3 n.d.
Kanebo 8g C19H18FN3O5S 0.8 7.3
Kanebo 8h C20H20FN3O5S 0.3 12.6
ON
ON
CH3
ON
CH3
CH3
ON
F
ON
OH
ON
OMe
R5
R6
R7 N
O
COOH
R8"
Appendix                                                                                                                                140
6. Metal - ion quinolones
Compound Structure Formula IC50 IC50 (TOX)
UL 1 [Cu(cf)2]Cl2 * 6 H2O 5.6 n.d.
UL 2 Not known (CfH2)(cfH)[CuCl4]Cl*H2O 3.6 n.d.
UL 3 ErxH2[FeCl4]Cl 21 n.d.
UL 4 (NfH2)(nfH)[ZnCl4]Cl*H2O 13.7 n.d.
UL 5 (CfH2)(cf)(BiCl6)*2 H2O 0.1 33
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7. Azetidinyl fluoroquinolones
Comp. R1 R2 R3 R4 R5 R6 A Formula IC50 IC50TOX
E-4535 CH3 H NH2 H c-C3H5 H CH C17H17FN3O3 Not active n.d.
E-4534 CH3 H NH2 H c-C3H5 H CF C17H16F2N3O3 Not active n.d.
E-4528 H CH3 NH
CH3
H c-C3H5 H CH C18H19FN3O3 Not active n.d.
E-4527 H CH3 NH
CH3
H c-C3H5 H CF C18H18F2N3O3 2.2 n.d.
E-4696 H NH2 H CH3 c-C3H5 H CH C17H18FN3O3 5.0 n.d.
E-4629 CH3 H NH2 H c-C3H5 H CH C17H18FN3O3 3.0 n.d.
E-4628 CH3 H NH2 H c-C3H5 H CF C17H17F2N3O3 3.0 n.d.
E-4591 CH3 NH2 H H c-C3H5 H CF C17H17F2N3O3 4.7 n.d.
E-4811 H H NH2 CH3 c-C3H5 H CF C17H17F2N3O3 Not active n.d.
E-4555 CH3 H NH2 H c-C3H5 H N C17H17F2N3O3 4.0 n.d.
E-4695 CH3 H NH2 CH3 c-C3H5 H N C16H17FN4O3 4.7 n.d.
E-4630 CH3 H NH2 H c-C3H5 H N C16H17FN4O3 3.3 n.d.
E-4715 H NH2 H CH3 c-C3H5 H CCl C17H17ClFN3O3 3.3 n.d.
E-5091 CH3 H NH2 H c-C3H5 H CCl C17H17ClFN3O3 Not active n.d.
E-4619 H NH2 H CH3 C2H5 H CF C17H19FN4O3 5.2 n.d.
E-5112 H NH2 H CH3 C2H5 NH2 CF C16H18F2N4O3 1.8 n.d.
E-4625 H NH2 H CH3 4-FPh H CF C20H16F3N3O3 2.3 n.d.
E-4626 H NH2 H CH3 2,4-
F2Ph
H CF C20H15F4N3O3 3.5 n.d.
E-4724 CH3 NH2 H CH3 2,4-
F2Ph
H CF C20H15F4N3O3 6.5 n.d.
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E-4685 H NH2 H CH3 2,4-
F2Ph
H N C19H15F3N4O3 1.3 n.d.
E-4936 CH3 H NH2 H 2,4-
F2Ph
H N C19H15F3N4O3 6.0 n.d.
E-4868 H NH2 H CH3 2,4-
F2Ph
H CH C20H16F3N3O3 Not active n.d.
E-4935 CH3 H NH2 H 2,4-
F2Ph
H CH C20H16F3N3O3 6.2 n.d.
E-5100 H NH2 H CH3 2,4-
F2Ph
NH2 CF C20H16F4N4O3 Not active n.d.
Compound R1 R2 R3 R4 R5 R6 Formula IC50 IC50
(TOX)
E-4548 H H NH2 H H CH3 C16H16F3N3O4 Not active n.d.
E-4487 H CH3 NH2 H CH3 H C17H18FN3O4 Not active n.d.
E-4497 H CH3 NH2 H H CH3 C17H18FN3O4 Not active n.d.
E-4654 H CH3 NHMe H H CH3 C18H20FN3O4 Not active n.d.
E-4549 H H NMe2 H H CH3 C18H20FN3O4 5.8 n.d.
E-4550 H CH3 NMe2 H H CH3 C19H22FN3O4 Not active n.d.
E-4572 H CH3 CH2NHEt H H CH3 C20H24FN3O4 Not active n.d.
E-4627 CH3 H NH2 H H CH3 C17H18FN3O4 8.8 n.d.
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Compound A R1 R2 R3 R4 Formula IC50 IC50
(TOX)
E-4889 N H CH3 H c-C3H5 C19H23ClFN5O4 Not active n.d.
E-4947 N CH3 H H c-C3H5 C19H23ClFN5O4 Not active n.d.
E-4972 N CH3 H H c-C3H5 C19H23ClFN5O4 Not active n.d.
E-4898 N H Isobutyl H c-C3H5 C22H19ClFN5O4 3.8 n.d.
E-4996 N H CH3 l-alanine c-C3H5 C22H28ClFN6O5 6.2 n.d.
E-5008 CH H CH3 H 2,4-
F2Ph
C30H29F3N4O7S Not active n.d.
E-5019 CH H n-
propyl
H 2,4-
F2Ph
C32H33F3N4O7S Not active n.d.
R4
NAN
F COOH
O
N
CH3
H
O
N
R1
R2
H
R3
Appendix                                                                                                                                144
8. N-1 Aryl substituted quinolones
Compound R2 R Formula IC50 IC50 (TOX)
H 1 H H C20H18FN3O3 8.7 n.d.
H 2 H o-OCH3 C21H20FN3O4 Not active n.d.
H 3 H o-CH3 C21H20FN3O3 Not active n.d.
H 4 H p-CH3 C21H20FN3O3 1.1 n.d.
H 5 H p-CF3 C21H17F4N3O3 5.2 n.d.
H 6 H o-F C20H17F2N3O3 Not active n.d.
H 7 H p-NO2 C20H17FN4O5 Not active n.d.
H 8 H m-OH C20H18FN3O4 22.4 n.d.
H 9 CH3 p- OCH3 C22H22FN3O4 Not active n.d.
H 10 CH3 m-OCH3 C22H22FN3O4 Not active n.d.
R2
N
N
F COOH
O
N
R
Appendix                                                                                                                                145
9. Dihydronicotine acids derivatives
Compound Structure Formula IC50 IC50 (TOX)
G-64070 C20H18N2O5 Not active n.d.
G-67012 C20H15Cl2NO4S Not active n.d.
G-71258 C17H13NO4S Not active n.d.
G-59030 C19H14N2O4S Not active n.d.
G-72800 C21H16FNO4 Not active n.d.
G-71286 C19H15NO4S Not active n.d.
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10. R-2/3 Derivatives
Compound R Formula IC50 IC50(TOX)
UV 1 C16H12N4O Not active n.d.
UV 3 C17H14N4O2 Not active n.d.
UV 5 C17H14N4O2 4.9 n.d.
UV 7 C16H11FN4O Not active n.d.
UV 9 C16H11BrN4O Not active n.d.
UV 11 C16H11ClN4O Not active n.d.
UV 13 C17H11F3N4O Not active n.d.
UV 14 C17H14N4O Not active n.d.
UV 16 C16H10Cl2N4O Not active n.d.
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Compound R Formula IC50 IC50(TOX)
UV 2 C17H13N5O 7.0 n.d.
UV 4 C18H15N5O2 3.4 n.d.
UV 6 C18H15N5O2 1.1 n.d.
UV 8 C17H12FN5O 2.0 n.d.
UV 10 C17H12BrN5O 5.9 n.d.
UV 12 C17H12ClN5O 4.4 n.d.
UV 15 C18H15N5O 4.0 n.d.
UV 17 C17H11Cl2N5O 6.9 n.d.
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11. Sulfanilyl Fluoroquinolones
Compound R1 R4 Formula IC50 IC50  (Tox)
NSFQ-104 C2H5 NH2 C22H23FSN4O5 2.2 n.d.
NSFQ-105 C3H5 NH2 C23H23FSN4O5 2.35 n.d.
CH3HNSNx C2H5 NHCH3 C23H25FSN4O5 1.6 n.d.
CH3HNScx C3H5 NHCH3 C24H25FSN4O5 1.6 n.d.
NO2SNx C2H5 NO2 C22H21FSN4O7 3.3 n.d.
NO2SCx C3H5 NO2 C23H21FSN4O5 4.6 n.d.
HSNx C2H5 H C22H22FSN2O5 1.8 n.d.
HSCx C3H5 H C23H22FSN2O5 1.9 n.d.
N(CH3)2SNx C2H5 N(CH3)2 C24H27FSN4O5 0.9 >250
N(CH3)2SCx C3H5 N(CH3)2 C25H27FSN4O5 Not active n.d.
CH3SNx C2H5 CH3 C23H24FSN3O5 2.1 n.d.
CH3SCx C3H5 CH3 C24H24FSN3O5 Not active n.d.
OCH3SNx C2H5 OCH3 C23H24FSN3O6 0.9 >250
OCH3SCx C3H5 OCH3 C24H24FSN3O6 Not active n.d.
Legend to Table 1-11: n.d. = not determined
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